Methods and compositions for nucleic acid sequencing

ABSTRACT

The present disclosure provides methods and systems for detecting multiple different nucleotides in a sample. In particular, the disclosure provides for detection of multiple different nucleotides in a sample utilizing fewer detection moieties than the number of nucleotides being detected and/or fewer imaging events than the number of nucleotides being detected.

The present application is a continuation of U.S. patent applicationSer. No. 15/207,892, filed on Jul. 12, 2016, now U.S. Pat. No.10,287,629, which is a continuation of U.S. patent application Ser. No.13/624,200, filed on Sep. 21, 2012, now U.S. Pat. No. 94,53,258, whichclaims priority to U.S. Application Ser. No. 61/619,878 filed Apr. 3,2012 and U.S. Application Ser. No. 61/538,294 filed Sep. 23, 2011, thedisclosures of which are incorporated herein by reference in theirentireties.

BACKGROUND

The detection of analytes such as nucleic acid sequences that arepresent in a biological sample has been used as a method for identifyingand classifying microorganisms, diagnosing infectious diseases,detecting and characterizing genetic abnormalities, identifying geneticchanges associated with cancer, studying genetic susceptibility todisease, and measuring response to various types of treatment. A commontechnique for detecting analytes such as nucleic acid sequences in abiological sample is nucleic acid sequencing.

Nucleic acid sequencing methodology has evolved significantly from thechemical degradation methods used by Maxam and Gilbert and the strandelongation methods used by Sanger. Today several sequencingmethodologies are in use which allow for the parallel processing ofthousands of nucleic acids all in a single sequencing run. Theinstrumentation that performs such methods is typically large andexpensive since the current methods typically rely on large amounts ofexpensive reagents and multiple sets of optic filters to record nucleicacid incorporation into sequencing reactions.

It has become clear that the need for high-throughput, smaller, lessexpensive DNA sequencing technologies will be beneficial for reaping therewards of genome sequencing. Personalized healthcare is moving towardthe forefront and will benefit from such technologies; the sequencing ofan individual's genome to identify potential mutations and abnormalitieswill be crucial in identifying if a person has a particular disease,followed by subsequent therapies tailored to that individual. Toaccommodate such an aggressive endeavour, sequencing should move forwardand become amenable to high throughput technologies not only for itshigh throughput capabilities, but also in terms of ease of use, time andcost efficiencies, and clinician access to instruments and reagents.

SUMMARY

Existing fluorescence based sequencing reactions distinguish between theincorporation of different nucleotides into a growing nucleic acidstrand by attaching a fluorescent moiety to each of four nucleotides, AT C and G. Typically, each of the fluorescent moieties excites and emitsat different wavelengths and thus the target sequence is determined.Conversely, the present disclosure provides for determination of asequence, for example a nucleic acid sequence, using a minimal dye set,minimal excitation light sources, and minimal optical emission filterswhile still allowing for differentiation of the incorporation of allfour nucleotides in a sequencing reaction. The present disclosureprovides methods and compositions amenable to any fluorescent systemwhere more than one analyte for detection is desired. However,particular advantages are found when applying the methods herein tosequencing methodologies such as sequence by synthesis methodologies.

Instruments and systems for detecting four color fluorescence sequencingare large and expensive to run, not only cost of the instrument but thereagents as well and are thus not very attractive to smaller and morecapital constrained locations. Methods and compositions that woulddecrease the costs and/or size associated with four color fluorescencedetection, for example for sequencing genomes, would provideinvestigators more efficient tools in terms of time efficiency, lowerreagent usage, smaller less expensive instrumentation, and the like foruse in their research endeavours.

Embodiments of the present disclosure provide those options by providinginvestigators with methods and compositions for determination of apolymer sequence, for example a nucleic acid sequence, comprising usinga minimal dye set, minimal light sources, and minimalexcitation/emission filters while still allowing for differentiation ofmonomer types (e.g., different nucleotides) incorporated in a sequencingreaction.

Embodiments described herein provide for determining the sequence of anucleic acid based on event timing and memorializing those events in“time space”. The present disclosure provides embodiments for the use ofone dye, or a plurality of dyes of the same or similarexcitation/emission spectra, or two or more dyes of differentfluorescence spectra, to determine the presence of analytes, for examplenucleotides, in a sample, using time space based imaging events. Asdescribed herein, time space sequencing reactions utilize one or morechemistries and imaging events or steps to differentiate between aplurality of analytes, for example four nucleotides, that areincorporated into a growing nucleic acid strand during a sequencingreaction.

In some embodiments, fewer than four different colours can be detectedin a mixture having four different nucleotides while still resulting inthe determination of the four different nucleotides, for example in asequencing reaction. As a first example, a pair of nucleotide types canbe detected at the same wavelength, but distinguished based on adifference in intensity for one member of the pair compared to theother, or based on a change to one member of the pair (e.g. via chemicalmodification, photochemical modification or physical modification) thatcauses apparent signal to appear or disappear compared to the signaldetected for the other member of the pair. As a second example, three offour different nucleotide types can be detected under particularconditions while a fourth nucleotide type lacks a label that isdetectable under those conditions, or is minimally detected under thoseconditions (e.g., minimal detection due to background fluorescence,etc). Incorporation of the first three nucleotide types into a nucleicacid can be determined based on presence of their respective signals andincorporation of the fourth nucleotide type into the nucleic acid can bedetermined based on absence or minimal detection of any signal. As athird example, one nucleotide type can include label(s) that aredetected in two different channels, whereas other nucleotide types aredetected in no more than one of the channels.

The aforementioned three exemplary configurations are not consideredmutually exclusive and can be used in various combinations. An exemplaryembodiment that combines all three examples, is a fluorescent-based SBSmethod that uses a first nucleotide type that is detected in a firstchannel (e.g. dATP having a label that is detected in the first channelwhen excited by a first excitation wavelength), a second nucleotide typethat is detected in a second channel (e.g. dCTP having a label that isdetected in the second channel when excited by a second excitationwavelength), a third nucleotide type that is detected in both the firstand the second channel (e.g. dTTP having at least one label that isdetected in both channels when excited by the first and/or secondexcitation wavelength) and a fourth nucleotide type that lacks a labelthat is not, or minimally, detected in either channel (e.g. dGTP havingno label).

In this example, an array of nucleic acid features can be treated withall four nucleotide types such that an extension event occurs atsubstantially all of the features prior to a detection event and thefeatures are detected in as few as one image event, in as few as twoimage events during the detection event. A first image obtained usingthe first excitation wavelength and emission in the first channel candetect and show features that incorporate the first and/or thirdnucleotide type (e.g. A and/or T). A second image obtained using thesecond excitation wavelength and emission in the second channel candetect and show features that incorporate the second and/or thirdnucleotide type (e.g. C and/or T). Unambiguous identification of thenucleotide type incorporated at each feature can be determined, forexample, by comparing the two images to arrive at the following:features that show up (i.e., are detected) maximally in the firstchannel incorporating the first nucleotide type (e.g. A), features thatshow up maximally in the second channel incorporating the secondnucleotide type (e.g. C), features that show up in both channelsincorporating the third nucleotide type (e.g. T) and features that don'tshow up, or are minimally detectable, in either channel incorporatingthe fourth nucleotide type (e.g. G).

Alternatively, the incorporation of the four nucleotides can bedetermined using only one combined imaging event. For example,incorporation of the labelled nucleotide types can be determined byexposing the incorporated nucleotides to two excitation wavelengths atone time (e.g., simultaneously) and capturing the emission spectra inone combined image. Unambiguous identification of the incorporatednucleotide types could be determined as previously stated; features thatshow up in one channel of the combined image would indicate theincorporation of that labelled nucleotide type (e.g., A), features thatshow up in the second channel of the combined image would indicate theincorporation of that labelled nucleotide type (e.g., C) and featuresthat show up in both channels would indicate the incorporation of athird nucleotide type (e.g., T). As one of the nucleotide types is notlabelled (e.g., G) incorporation is determined by absence of, orminimally measurable, features in both channels for that unlabellednucleotide. Note that the location of the features that incorporate G inthis example can be determined from other cycles (where at least one ofthe other three nucleotide types is incorporated).

In one embodiment of the present disclosure, methods are provided fordetermining the sequence of a polynucleotide comprising detecting in asequencing reaction the incorporation of three different types ofdetectable nucleotide conjugates into a polynucleotide and determiningthe incorporation of a fourth type of nucleotide based on the detectionpattern of the three different types of detectable nucleotides into thepolynucleotide thereby determining the sequence of a polynucleotide,wherein the incorporation of three different types of detectablenucleotide conjugates is detected from a signal state and wherein theincorporation of the fourth type of nucleotide is determined from a darkstate.

In another embodiment, the present disclosure provides methods fordetermining the sequence of a polynucleotide comprising applying to apolynucleotide sample for sequencing a solution comprising four modifiednucleotide types wherein three modified nucleotide types are conjugatedto one or more detection moieties and one or more linkers positionedbetween the nucleotide and the one or more detection moieties, andwherein a fourth nucleotide type lacks a detection moiety, detecting apattern of incorporation of said modified nucleotides in a sequencingreaction thereby capturing a first detectable pattern, applying one ormore compositions to the sequencing reaction thereby changing the firstdetectable pattern, detecting a second detectable pattern, anddetermining the sequence of the polynucleotide sample based on thedetectable patterns.

In some embodiments, the polynucleotide for sequencing comprises one ormore of deoxyribonucleic acids, modified deoxyribonucleic acids,ribonucleic acids and modified ribonucleic acids. In some embodiments,the polynucleotide for sequencing is a genomic DNA library preparation.In some embodiments, the nucleotide conjugate comprises nucleotide typesselected from the group consisting of dATP, dTTP, dUTP, dCTP, dGTP ornon-natural nucleotide analogs thereof. In some embodiments, thenon-natural nucleotide analog comprises a reversible terminator moietyand is selected from the group consisting of rbATP, rbTTP, rbCTP, rbUTPand rbGTP. In some embodiments, the nucleotide incorporation is sequenceby synthesis, sequence by ligation, and sequence by hybridization or acombination thereof. In some embodiments, the three nucleotide typeconjugates are detected by detecting a fluorescent moiety. In someembodiments, the fluorescent moiety is the same for the three nucleotideconjugates whereas in other embodiments the fluorescent moiety is one ormore different fluorescent moieties. In some embodiments, the one ormore different fluorescent moieties are detected by the same emissionfilter. In some embodiments, the fluorescent moiety comprises afluorescent resonance energy transfer system moiety. In someembodiments, the incorporation of the fourth nucleotide is determined bylack of detection. In some embodiments, the detectable nucleic acidconjugates are detected by fluorescence. In some embodiments, thefluorescence is detected by a first and a second imaging event, infurther embodiments the first and second imaging events are separated intime. In some embodiments, the first imaging event detects a pattern offluorescence that is different from the pattern of fluorescence detectedby the second imaging event. In some embodiments, the incorporation ofone or more nucleotides is determined by the difference in the patternof fluorescence between the first and second imaging events. In someembodiments, the one or more nucleotide type conjugates further compriseone or more linker sequences, in further embodiments the one or morelinker sequences comprise one or more of a cleavable linker and a spacerlinker. In some embodiments, the cleavable linker comprises one or morecleavable linkage groups selected from the group consisting of adisulfide, a diol, a diazo, an ester, a sulfone, an azide, an alyl and asilyl ether, whereas in preferred embodiments the cleavable linkagegroup is a disulfide. In some embodiments, the spacer linker is one ormore of polyethylene glycol or concatamers thereof and2-{2-[3-(2-amino-ethylcarbomyl)-phenoxyl-1-azido-ethoxy}-ethoxy-aceticacid. In some embodiments, the one or more spacer linkers furthercomprise one or more cleavable linkage groups wherein the cleavablelinkage group is selected from the group consisting of a disulfide, adiol, a diazo, an ester, a sulfone, an azide, an alyl and a silyl ether.In some embodiments, the spacer linker is polyethylene glycol orconcatamers thereof whereas in other embodiments the spacer linker is2-{2-[3-(2-amino-ethylcarbomyl)-phenoxyl-1-azido-ethoxy}-ethoxy-aceticacid. In some embodiments, the one or more nucleotide conjugatescomprise a polyethylene glycol linker and a2-{2-[3-(2-amino-ethylcarbomyl)-phenoxyl-1-azido-ethoxy}-ethoxy-aceticacid linker which may or may not further comprise a hapten and afluorescent moiety. In some embodiments, the hapten is selected from thegroup consisting of biotin, digoxigenin and dinitrophenol. In someembodiments, the one or more nucleotide conjugates comprises astreptavidin-fluorescent moiety conjugate whereas in other embodiments,the one or more nucleotide conjugates comprises an anti-haptenantibody-fluorescent moiety conjugate selected from the group consistingof anti-digoxigenin and anti-dinitrophenol. In some embodiments thenucleotide conjugate comprising a polyethylene glycol linker and a2-{2-[3-(2-amino-ethylcarbomyl)-phenoxyl-1-azido-ethoxy}-ethoxy-aceticacid linker further comprises two fluorescent moieties. In someembodiments, the two fluorescent moieties constitute a fluorescenceresonance energy transfer system.

An additional embodiment of the present disclosure provides acomposition for sequencing a nucleic acid comprising three modifiednucleotide types detectable by a fluorescent moiety and a fourthmodified nucleotide type, wherein said fourth modified nucleotide typeis not detectable by a fluorescent moiety, and wherein the incorporationof the four modified nucleotide types in the composition into asequencing reaction is determined by the fluorescent detection of thethree detectable modified nucleotide types in the composition. In someembodiments, the compositional nucleic acid comprises DNA from a DNAlibrary preparation. In some embodiments, the modified nucleotide typecomprises a reversible terminator moiety and is selected from the groupcomprising of rbATP, rbTTP, rbUTP, rbCTP and rbGTP. In some embodiments,the sequencing reaction is sequence by synthesis, sequence by ligationor sequence by hybridization. In some embodiments, the fluorescentmoiety is the same for the three modified nucleotides. In someembodiments, the fluorescent moiety is one or more different fluorescentmoieties which are preferably detected by the same emission filter. Insome embodiments, the incorporation of three modified nucleotide typesis determined by a first fluorescent imaging pattern and a secondfluorescent imaging pattern. In some embodiments, the incorporation ofthe fourth nucleotide type is determined by the fluorescence imagingpatterns of the other three nucleotide types. In some embodiments, thecompositions described herein comprising the one or more of the modifiednucleotide types further comprise one or more linker sequences. In someembodiments, the one or more linker sequences comprise one or more of acleavable linker and a spacer linker, wherein the cleavable linkercomprises one or more cleavable linkage groups selected from the groupconsisting of a disulfide, a diol, a diazo, an ester, a sulfone, anazide, an alyl and a silyl ether, preferably the cleavable linkage groupis disulfide. In some embodiments, the spacer linker is one or more ofpolyethylene glycol or concatamers thereof and2-{2-[3-(2-amino-ethylcarbomyl)-phenoxyl-1-azido-ethoxy}-ethoxy-aceticacid, wherein concatamers of polyethylene glycol include between fourand twelve polyethylene glycol molecules are sometime preferred. In someembodiments, the one or more spacer linkers further comprise one or morecleavable linkage groups as previously described. In some embodiments,the one or more of three modified nucleotide types comprise apolyethylene glycol linker and a2-{2-[3-(2-amino-ethylcarbomyl)-phenoxyl-1-azido-ethoxy}-ethoxy-aceticacid linker, whereas some preferred embodiments further comprise ahapten and a fluorescent moiety. In some embodiments, the hapten isselected from the group consisting of biotin, digoxigenin anddinitrophenol. In some embodiments, the hapten is detected by a haptenbinding partner-fluorescent moiety conjugate or an anti-haptenantibody-fluorescent moiety conjugate. In some embodiments, theanti-hapten antibody is selected from anti-digoxigenin andanti-dinitrophenol. In some embodiments, said hapten binding partner isstreptavidin. In some embodiments, said modified nucleotide typesdetectable by a fluorescent moiety are conjugated to one or more of acleavable linker and a spacer linker or a combination thereof, wherein alinker is conjugated to a fluorescent moiety or a hapten, and wherein amodified nucleotide that is not detectable by a fluorescent moiety isnot so conjugated.

An additional embodiment as disclosed herein provides a method fordetermining a plurality of nucleic acid sequences comprising providing asample comprising plurality of different nucleic acids, each nucleicacid comprising a template and primer; performing a cycle of asequencing reaction, wherein the cycle comprises extending the primersfor the nucleic acids in the sample to form a plurality of extendedprimers having at least four different nucleotide types, thereby formingan extended sample, acquiring a first collection of signals from theextended sample, wherein no more than three of the different nucleotidetypes in the extended primers are in a signal state and wherein at leastone of the different nucleotide types in the extended primers is in adark state; treating the extended sample with a modifying reagent,wherein at least one of the different nucleotide types in the extendedprimers is modified, thereby producing a modified sample, and acquiringa second collection of signals from the modified sample, wherein atleast one of the different nucleotide types is in different state in thefirst collection of signals compared to the second collection ofsignals; and determining sequences for the plurality of differentnucleic acids by evaluating the first collection of signals and thesecond collection of signals from the cycles. In some embodiments, theplurality of different nucleic acids is attached to a substrate. In someembodiments, the extending of the primers comprises polymerase catalyzedaddition of the different nucleotide types. In some embodiments, thedifferent nucleotide types comprise reversible blocking moieties,whereby a single nucleotide type is added to each of the extendedprimers in each of the cycles. In some embodiments, the extending of theprimers comprises ligase catalyzed addition of oligonucleotidescomprising the different nucleotide types. In some embodiments, no morethan two of the different nucleotide types in the extended primers arein a signal state during the acquiring of the first collection ofsignals from the extended sample, whereas in other embodiments at leasttwo of the different nucleotide types in the extended primers are in adark state during the acquiring of the first collection of signals fromthe extended sample. In some embodiments one of the different nucleotidetypes in the extended primers is in a dark state during the acquiring ofthe first collection of signals from the extended sample. In someembodiments, the treating of the extended sample with a modifyingreagent comprises removing a label from a nucleotide type or adding alabel to a nucleotide type. In some embodiments, at least two of thedifferent nucleotide types in the extended primers is modified by thetreating of the extended sample with a modifying reagent, whereas inother embodiments no more than 3 of the different nucleotide types inthe extended primers are modified by the treating of the extended samplewith a modifying reagent. In some embodiments the extending of theprimers for the nucleic acids in the sample forms a plurality ofextended primers having no more than four different nucleotide types,whereas in other embodiments the extending of the primers for thenucleic acids in the sample forms a plurality of extended primers havingat least five different nucleotide types. In some embodiments, two ofthe different nucleotide types complement the same nucleotide in thenucleic acid and wherein a first of the two different nucleotide typesis in a signal state during the acquiring of the first collection ofsignals and wherein a second of the two different nucleotide types is ina dark state during the acquiring of the first collection of signals. Insome embodiments, the first of the two different nucleotide types is ina dark state during the acquiring of the second collection of signals.In some embodiments, the second of the two different nucleotide types isin a signal state during the acquiring of the second collection ofsignals. In preferred embodiments, a sequencing reaction cycle aspreviously described is repeated one or more times.

In another embodiment, the present disclosure provides a method fordetermining the sequence of a polynucleotide comprising detecting byimaging events the incorporation of three different types of detectablenucleotide conjugates into a polynucleotide and determining theincorporation of a fourth type of nucleotide based on the detectionpattern of the three different types of detectable nucleotides into thepolynucleotide, wherein detecting comprises fewer imaging events thandifferent types of detectable nucleotide conjugates. In someembodiments, the polynucleotide comprises one or more ofdeoxyribonucleic acids, modified deoxyribonucleic acids, ribonucleicacids or modified ribonucleic acids. In some embodiments, the nucleotideconjugate comprises nucleotide types selected from the group consistingof dATP, dTTP, dUTP, dCTP, dGTP or non-natural nucleotide analogsthereof wherein the non-natural nucleotide analog comprises a reversibleterminator moiety and is selected from the group consisting of rbATP,rbTTP, rbCTP, rbUTP and rbGTP. In some embodiments, the nucleotideincorporation is sequence by synthesis, sequence by ligation or sequenceby hybridization. In some embodiments, the three nucleotide typeconjugates are detected by detecting a fluorescent moiety, wherein thefluorescent moiety is the same for the three nucleotide conjugates orwherein the fluorescent moiety is one or more different fluorescentmoieties. In some embodiments, one or more different fluorescentmoieties are detected by the same emission filter. In some embodiments,the fluorescent moiety comprises a fluorescent resonance energy transfersystem moiety. In some embodiments, the incorporation of the fourthnucleotide is determined by lack of detection. In some embodiments, thedetectable nucleic acid conjugates are detected by fluorescence whereinthe fluorescence is detected by the imaging events. In some embodiments,the imaging events comprise a first and a second imaging event forexample which are separated in time. In some embodiments, the firstimaging event detects a pattern of fluorescence that is different fromthe pattern of fluorescence detected by the second imaging event. Insome embodiments, the incorporation of one or more nucleotides isdetermined by the difference in the pattern of fluorescence between thefirst and second imaging events. In some embodiments, the one or morenucleotide type conjugates further comprise one or more linker sequencescomprising one or more of a cleavable linker and a spacer linker. Insome embodiments, the cleavable linker comprises one or more cleavablelinkage groups selected from the group consisting of a disulfide, adiol, a diazo, an ester, a sulfone, an azide, an alyl and a silyl ether,preferably the cleavable linkage group is a disulfide. In someembodiments, the spacer linker is one or more of polyethylene glycol orconcatamers thereof and2-{2-[3-(2-amino-ethylcarbomyl)-phenoxyl-1-azido-ethoxy}-ethoxy-aceticacid. In some embodiments, the one or more spacer linkers furthercomprise one or more cleavable linkage groups wherein the cleavablelinkage group is selected from the group consisting of a disulfide, adiol, a diazo, an ester, a sulfone, an azide, an alyl and a silyl ether.In some embodiments, the spacer linker is polyethylene glycol orconcatamers thereof or2-{2-[3-(2-amino-ethylcarbomyl)-phenoxyl-1-azido-ethoxy}-ethoxy-aceticacid or both. In some embodiments, the nucleotide conjugate comprising apolyethylene glycol linker and a2-{2-[3-(2-amino-ethylcarbomyl)-phenoxyl-1-azido-ethoxy}-ethoxy-aceticacid linker further comprises a hapten and a fluorescent moiety whereinthe hapten is selected from the group consisting of biotin, digoxigeninand dinitrophenol. In some embodiments, the one or more nucleotideconjugates comprises a streptavidin-fluorescent moiety conjugate. Insome embodiments, the one or more nucleotide conjugates comprises ananti-hapten antibody-fluorescent moiety conjugate selected from thegroup consisting of anti-digoxigenin and anti-dinitrophenol. In someembodiments, the nucleotide conjugate comprising a polyethylene glycollinker and a2-{2-[3-(2-amino-ethylcarbomyl)-phenoxyl-1-azido-ethoxy}-ethoxy-aceticacid linker further comprises two fluorescent moieties. In someembodiments, the two fluorescent moieties constitute a fluorescenceresonance energy transfer system. In some embodiments, the one or morenucleotide conjugates further comprise a hapten or a fluorescent moiety,wherein the hapten is selected from the group consisting of biotin,digoxigenin and dinitrophenol. In some embodiments, the one or morenucleotide conjugates comprises a streptavidin-fluorescent moietyconjugate. In some embodiments, the detecting one or more nucleotideconjugates comprises an anti-hapten antibody-fluorescent moietyconjugate selected from the group consisting of anti-digoxigenin andanti-dinitrophenol.

FIGURES

FIG. 1 shows exemplary cloud type heat maps, or cloud plots, for cyclesin a sequencing reaction. The plots represent the composite of image 1(x axis) and image 2 (y axis), such that the plots represent thefluorescence image after a complete cycle. The location of A, C, G and Tin the cloud plot is demonstrated in the bottom cloud plot map.

FIG. 2 shows exemplary graphs reporting percentage (Y axis) error rates(top) and blank base calls (bottom) in a sequencing reaction on a cycleby cycle basis (X axis).

FIG. 3 shows A) emission spectra for two exemplary dyes and B) anexemplary cloud plot for a sequencing cycle when practicing theembodiment of using two dyes of different fluorescence spectra forsequencing.

FIG. 4 shows A) emission spectra for two exemplary dye sets and B) anexemplary cloud plot for a sequencing cycle when practicing theembodiment of using two dye sets of different emission spectra forsequencing.

FIG. 5 shows A) the error rate of basecalls for an experiment using onedye in a sequencing reaction, B) exemplary fluorescent patterns for eachof the modified nucleotides in a first image event (Image 1) using onlyone dye, C) exemplary fluorescent patterns for each of the modifiednucleotides in a second image event (Image 2) using only one dye, and D)a cloud plot combining the first and second imaging events from asequencing reaction wherein only one dye and two imaging events are usedto differentiate between the four different nucleotides present forincorporation during a sequencing reaction.

FIGS. 6-8 show grids and tables illustrating alternative strategies fordetecting and determining nucleotide incorporation in a sequencingreaction using one fluorescent dye (or two dyes of same or similarexcitation/emission spectra) and two imaging steps.

FIGS. 9 and 10 depict grids and tables illustrating alternativestrategies for detecting and determining nucleotide incorporation in asequencing reaction using one fluorescent dye (or two dyes of same orsimilar excitation/emission spectra) and one imaging step.

FIGS. 11 and 12 illustrate two exemplary sequencing work flows accordingto the present invention.

DETAILED DESCRIPTION

Current fluorescence based technologies utilized for differentiatingbetween different analytes in a sample, such as found in sequencingtechnologies (i.e., fluorescence sequencing technologies) are predicatedon, for example, the quality of a signal as generated by a detectionmoiety that is associated with a particular type of nucleotide. Forexample, traditional fluorescent sequencing technologies utilizeidentifiably distinct fluorescent moieties, each attached to one of thefour nucleotides A, T, C and G that are utilized in a sequencingreaction. Fluorescently labelled nucleotides utilized during asequencing reaction, regardless of their method of utilization, aretypically excited and measured by one of four optical filters (i.e., onefor each distinct dye) in a fluorescent sequencing instrument. Sequenceby synthesis (SBS) technology as well as dye terminator sequencingtechnology utilizing dideoxynucleotides, are exemplary of four channelfluorescence based sequencing technologies. Fluorescence basedsequencing instrumentation is typically large, expensive andunattractive to smaller and more capital constrained milieus. Newsequencing technologies typically utilize innovative methods, systemsand compositions in order to move forward in becoming more accurate(i.e., fewer errors), having higher throughput capacity (i.e., moregenomes sequences per given time period) and/or reducing costs (i.e.,<$10,000/genome), and desirably have a footprint not to exceed a smallspace on an investigator's benchtop.

The present disclosure provides solutions for advancing the field ofnucleic acid sequencing. Embodiments disclose methods and compositionsthat utilize minimal detection moieties, for example preferably one dye,or a plurality of dyes with similar detection characteristics, whendetecting and differentiating multiple different analytes, such asdifferent nucleotide types, in a sample, for example for samplesequencing. Further, the present disclosure provides methods fordetermining the incorporation of four nucleotides into a sequencingreaction using less than four detection filters and fewer imaging steps.The use of less than four filters and hence fewer imaging steps allowsfor sequencing to be performed on smaller formats since fewer excitationand emission filters need to be present. It is contemplated that themethods and systems as described herein decrease instrument hardwareneeds, decrease the size of an instrument, reagent usage and costs whileincreasing data output.

In particular embodiments, methods are provided for determining asequence of monomeric subunits in a polymer. The methods are exemplifiedherein with regard to nucleic acid polymers and their nucleotidesubunits, but can be carried out for other polymers and their subunits.Although the methods can be used for samples having a single polymersequence, the methods provide particular advantages when used todistinguish several different subunit types in a sample having polymerswith many different sequences (i.e. a multiplex polymer sample). Forexample, in some embodiments the methods provide the ability todistinguish a number of different subunit types in a sample that isgreater than the number of different signal types that are acquired fromthe sample. In the case of a nucleic acid sample, a data acquisitionstep can be performed on the sample to acquire a collection of less thanfour different signal types and yet the sequence location for all fourof the different nucleotide types can be determined for the sample.

Several aspects of the methods, individually or in combination, providethe ability to distinguish a number of different subunit types (e.g.,different nucleotide types, different dideoxynucleotide types, modifieddideoxynucleotide types, reversibly bound modified nucleotide types,etc.) in a polymer sample that is greater than the number of differentsignal types acquired from the polymer sample. The aspects can include,but are not limited to, correlating one or more monomeric subunit typeto a dark state, correlating one or more monomeric subunit type to asignal state, correlating one or more monomeric subunit type to a greystate, or correlating one or more monomeric subunit type to a change instate between a dark state, grey state or signal state. A “signalstate,” when used in reference to a detection event, means a conditionin which a specific signal is produced in the detection event. Forexample, a nucleotide subunit can be in a signal state and detectablewhen attached to a fluorescent label that is detected in a fluorescencedetection step by excitation and emission of that fluorescent label in asequencing method. The term “dark state,” when used in reference to adetection event, means a condition in which a specific signal is notproduced in the detection event. For example, a nucleotide subunit canbe in a dark state when the nucleotide lacks a fluorescent label and/ordoes not emit fluorescence that is specifically detected in afluorescent detection step of a sequencing method. Dark state detectionmay also include any background fluorescence which may be present absenta fluorescent label. For example, some reaction components maydemonstrate minimal fluorescence when excited at certain wavelengths. Assuch, even though there is not a fluorescent moiety present there may bebackground fluorescence from such components. Further, backgroundfluorescence may be due to light scatter, for example from adjacentsequencing reactions, which may be detected by a detector. As such,“dark state” can include such background fluorescence as when afluorescent moiety is not specifically included, such as when anucleotide lacking a fluorescent label is utilized in methods describedherein. However, such background fluorescence is contemplated to bedifferentiatable from a signal state and as such nucleotideincorporation of an unlabelled nucleotide (or “dark” nucleotide) isstill discernible. The term “grey state,” when used in reference to adetection event, means a condition in which an attenuated signal isproduced in the detection event. For example, a population ofnucleotides of a particular type can be in a grey state when a firstsubpopulation of the nucleotides attached to a fluorescent label that isdetected in a fluorescence detection step of a sequencing method while asecond subpopulation of the nucleotides lacks the fluorescent label anddoes not emit fluorescence that is specifically detected in thefluorescent detection step.

In particular embodiments, a method for sequencing a polymer is carriedout in cycles, wherein an individual cycle includes one or more stepsused to distinguish a monomer at a particular position in the polymer. Acycle can comprise a detection event in some embodiments. However, asequencing cycle need not include a detection event, for example, ifdetection is carried out after steps are carried out to distinguish oneor more monomers in a polymer. For example, a detection event can occurhalfway through a cycle, at the end of one cycle, at the end of 1½cycles, at the end of two cycles, at the end of 2½ cycles, at the end ofthree cycles, etc. A further aspect of the methods that can provide theability to distinguish a number of different subunit types in a polymersample that is greater than the number of different signal typesacquired from the polymer sample, is the use of two or more signalacquisition steps and at least one nucleotide modification step duringan individual sequencing cycle. As such, a sequencing method can includeseveral cycles of nucleotide addition and the cycles can includeorthogonal steps of acquiring signals from the sequencing sample, thenmodifying one or more nucleotides in the sequencing sample to changetheir state (e.g. between a signal state, dark state or grey state), andthen acquiring a second set of signals from the sequencing sample.Several examples are set forth in further detail below in whichparticular nucleotide types are in a signal state due to an attachedfluorescent label, particular nucleotide types are in a dark state dueto the absence of the label, particular nucleotides are converted from asignal state to a dark state by cleaving a linker that attaches afluorescent label and/or particular nucleotides are converted from adark state to a signal state by binding a receptor (e.g. antibody orstreptavidin) that recruits a fluorescent label to the nucleotide thatdid not otherwise have the label.

In lieu of detecting differences in the quality of a fluorescent signal,for example as practiced for some fluorescent sequencing technologies,the present disclosure provides for detection of multiple differentanalytes (i.e., nucleotides, proteins, or fragments thereof) in areaction by distinguishing between differences in detection of onefluorescent moiety, or two fluorescent moieties of same or similarexcitation/emission spectra (i.e., excited by same laser and emissioncaptured by same optical filter), at different times during a reaction,for example pre and post a change in reaction conditions. In someembodiments, methods for detecting and determining an analyte comprisesdetecting fluorescence output at two different times during a reactioncycle.

Typically, a reaction cycle will be carried out by delivering at leastfour nucleotide types to a nucleic acid sample in the presence of apolymerase, for example a DNA or RNA polymerase, during a primerextension reaction. The presence of at least four nucleotide typesprovides an advantage of increasing polymerase fidelity compared to theuse of fewer than four nucleotide types. The use of orthogonal steps toconvert one or more incorporated nucleotide types from one state toanother state allows multiple nucleotide types to be presentsimultaneously during a polymerase extension reaction, therebyincreasing fidelity while also allowing a single label type to bedetected in each cycle, which serves to provide more simplified optics.Use of simplified optics is preferential as compared to systems thatrely on more complex optics to record output from multiple differentlabels to distinguish different nucleotide types that are presentsimultaneously in an extension reaction. It is further contemplated thatin some embodiments fewer that four different types of nucleotides canbe present during a polymerase extension reaction.

Certain illustrative embodiments are described below. The compositionsand their methods of use are not limited to these embodiments.

In some embodiments, methods for sequencing a nucleic acid comprise theuse of one fluorescent moiety for direct or indirect detection of threedifferent nucleotide types and one nucleotide type that is not detectedby the presence of a fluorescent signal but is instead detected by alack or absence of a fluorescent signal. In some embodiments, methodsfor sequencing a nucleic acid comprise the use of two or more differentfluorescent moieties that comprise the same or similarexcitation/emission spectra for direct or indirect detection of threedifferent nucleotide types and one nucleotide type that is not detectedby the presence of a fluorescent signal but is instead detected by alack or absence of fluorescent signal. The same or similar excitationand emission spectra are such that a laser excites the two or moredifferent fluorescent moieties and an optical filter captures theiremitted fluorescence signals. Detection of fluorescence to determine thesequence of a nucleic acid sample is performed in time space, forexample at different times during a sequencing reaction (i.e., pre andpost a change in reaction conditions such as enzymatic cleavage, changein environmental pH, addition of additional reagents), providingpatterns of fluorescence such as fluorescence transitions patterns,their cumulative patterns determining the sequence of the nucleic acidtarget. As such, the methods described herein are time and costefficient and allow for simplification of associated sequencinginstrumentation.

An exemplary application of utilizing time space fluorescence patterndifferences for determining a target nucleic acid sequence is sequenceby synthesis (SBS) methodologies and technologies. As such, embodimentsas described herein find particular utility in sequence by synthesisfluorescent applications. Even though embodiments as described hereinare exemplary of innovative methods of fluorescent sequencing, thedisclosed embodiments also find utility for a variety of otherapplications where detection of more than one analyte (i.e., nucleotide,protein, or fragments thereof) in a sample is desired.

In developing embodiments for sequencing using a minimal dye set,experimentation revealed alternative strategies for distinguishingbetween nucleotide incorporations using only one or two fluorescentmoieties. These strategies provide for all four nucleotide types to besimultaneously present in a sequence cycle, and for the use of minimaldyes and optical filter sets. In some embodiments, no more than threefluorescent moieties are utilized to determine the incorporation of allfour nucleotide types that are present during a reaction, using one ortwo excitation and emission filters. In preferred embodiments no morethan one fluorescent moiety (or two or three of same or similarexcitation/emission spectra) is utilized to determine the incorporationof all four nucleotide types that are all present during a reaction,using one excitation range of light and one detection emission filter.It will be understood that, in some embodiments, more than onefluorescent moiety (or moieties of more than one excitation range oremission range) can be used.

In some embodiments, sequencing using a minimal dye set is performed ona substrate, such as a glass, plastic, semiconductor chip or compositederived substrate. In some embodiments, one nucleic acid species isprovided on a substrate for example for single target sequencing. Inother embodiments, sequencing can also be in a multiplex format, whereinmultiple nucleic acid targets are detected and sequenced in parallel,for example in a flowcell or array type of format. Embodiments describedherein are particularly advantageous when practicing parallel sequencingor massive parallel sequencing. Platforms practicing fluorescentparallel sequencing include, but are not limited to, those offered byIllumina, Inc. (e.g., HiSeq, Genome Analyzer, MiSeq, iScan platforms),Life Technologies (e.g., SOLiD), Helicos Biosciences (e.g., Heliscope),454/Roche Life Sciences (Branford, Conn.) and Pacific Biosciences (e.g.,SMART). Flowcells, chips, and other types of surfaces that mayaccommodate multiple nucleic acid species are exemplary of substratesutilized for parallel sequencing. In multiplex formats wherein multiplenucleic acid species are sequenced in parallel, clonally amplifiedtarget sequences (e.g., via emulsion PCR (emPCR) or bridgeamplification) are typically covalently immobilized on a substrate. Forexample, when practicing emulsion PCR the target of interest isimmobilized on a bead, whereas clonally amplified targets areimmobilized in channels of a flowcell or specific locations on an arrayor chip.

Flowcells for use with compositions and methods as described herein canbe used in sequencing in a number of ways. For example, a DNA samplesuch as a DNA library can be applied to a flowcell or fluidic devicecomprising one or more etched flow channels, wherein the flowcell canfurther comprise a population of probe molecules covalently attached toits surface. The probes attached in the flowcell channels areadvantageously located at different addressable locations in the channeland DNA library molecules can be added to the flowcell channels whereincomplementary sequences can bind (as described herein, further asdescribed in provisional U.S. Patent Application 61/431,425 which isincorporated herein by reference in its entirety). Another example of aflowcell for use in the present application comprises a CMOS flowcell asdescribed in provisional U.S. Patent Application 61/625,051 which isincorporated herein by reference in its entirety. Bridge amplificationcan be performed as described herein followed by sequencing by synthesismethods and compositions as described herein. Methods for creating andutilizing flowcells for sequencing are known in the art; references towhich are provided herein and all of which are incorporated herein byreference in their entireties. It is contemplated that the methods andcompositions as described herein are not limited to any particularmanufacture or method of flowcell directed sequencing methodologies.

Sequencing utilizing the methods and compositions described herein canalso be performed in a microtiter plate, for example in high densityreaction plates or slides (Margulies et al., 2005, Nature 437(7057):376-380, incorporated herein by reference in its entirety). For example,genomic targets can be prepared by emPCR technologies. Reaction platesor slides can be created from fiber optic material capable of capturingand recording light generated from a reaction, for example from afluorescent or luminescent reaction. The core material can be etched toprovide discrete reaction wells capable of holding at least one emPCRreaction bead. Such slides/plates can contain over a 1.6 million wells.The created slides/ plates can be loaded with the target sequencingreaction emPCR beads and mounted to an instrument where the sequencingreagents are provided and sequencing occurs.

An example of arrayed substrates for sequencing targets utilizingcompositions and methods as disclosed herein is provided when practicingpatterned substrates comprising DNA nanoballs on a chip or slide asperformed by Complete Genomics (Mountain View, Calif.). As described inDrmanac et al., 2010, Science 327(5961): 78-81, a silicon wafer can belayered with silicon dioxide and titanium and subsequently patternedusing photolithography and dry etching techniques. The wafer can betreated with HMDS and coated with a photoresist layer to define discreteregions for silanization and subsequent covalent attachment of DNAnanoballs for sequencing. A skilled artisan will appreciate that manymethods exist for creating slides/chips with discrete locations forimmobilization of nucleic acids for use in sequencing methodologies andthe present methods are not limited by the method in which a substrateis prepared for sequencing.

For purposes of illustration and not intended to limit embodiments asdescribed herein, a general strategy sequencing cycle can be describedby a sequence of steps. The following example is based on a sequence bysynthesis sequencing reaction, however the methods as described hereinas not limited to any particular sequencing reaction methodology.

The four nucleotide types A, C, T and G, typically modified nucleotidesdesigned for sequencing reactions such as reversibly blocked (rb)nucleotides (e.g., rbA, rbT, rbC, rbG) wherein three of the four typesare fluorescently labelled, are simultaneously added, along with otherreaction components, to a location where the template sequence ofinterest is located and the sequencing reaction occurs (e.g., flowcell,chip, slide, etc.). Following incorporation of a nucleotide into agrowing sequence nucleic acid chain based on the target sequence, thereaction is exposed to light and fluorescence is observed and recorded;this constitutes a first imaging event and a first fluorescencedetection pattern. Following the first imaging event, one or moreadditional chemical reagents may be added to the sequencing reactionwhereby the added reagent(s) may change the intensity of thefluorescence or some other chemical aspect of the first reaction whichcauses an identifiable and measurable change in fluorescence (i.e. afluorescence transition change). The reaction location is once againilluminated and any change in fluorescence is captured and recorded;constituting a second imaging event (i.e., a second fluorescencedetection pattern). Blockers present on the incorporated nucleotides areremoved and washed away along with other reagents present after thesecond imaging event in preparation for the next sequencing cycle.Exemplary chemical reagents include, but are not limited to, cleavagereagents, binding partner-fluorescent moiety conjugates, or otherreagents that may directly or indirectly cause an identifiable andmeasurable change in fluorescence from the first imaging event to thesecond imaging event. The fluorescence patterns from the two imagingevents are compared and nucleotide incorporation, and thus the sequenceof the target nucleic acid, for that particular cycle is determined. Theexemplary general strategy cycle utilizes preferably one fluorescentmoiety (or more than one of same or similar excitation/emission) and oneemission detection filter to determine incorporation of the fourdifferent nucleotide types into a sequencing reaction.

One avenue of differentiating between the different strategies fordetecting nucleotide incorporation in a sequencing reaction using onefluorescent dye (or two or more dyes of same or similarexcitation/emission spectra) is by characterizing the incorporations interms of the presence or relative absence, or levels in between, offluorescence transition that occurs during a sequencing cycle. As such,sequencing strategies can be exemplified by their fluorescent profilefor a sequencing cycle. For strategies disclosed herein, “1” and “0”denotes a fluorescent state in which a nucleotide is in a signal state(e.g. detectable by fluorescence) (1) or whether a nucleotide is in adark state (e.g. not detected or minimally detected at an imaging step)(0). A “0” state does not necessarily refer to a total lack, or absenceof signal. Although in some embodiments there may be a total lack orabsence of signal (e.g. fluorescence). Minimal or diminishedfluorescence signal (e.g. background signal) is also contemplated to beincluded in the scope of a “0” state as long as a change in fluorescencefrom the first to the second image (or vice versa) can be reliablydistinguished.

In one embodiment, an exemplary strategy for detecting and determiningnucleotide incorporation in a sequencing reaction using one fluorescentdye (or two dyes of same or similar excitation/emission spectra) and twoimaging events is exemplified by the grid and detection table shown inFIG. 6. The grid and detection table represent the theoretical spacedepiction of sequencing data as visualized in the heat map, or cloudplots, for example as seen in FIG. 1.

In some embodiments of sequencing by synthesis (SBS), four modifiednucleotide triphosphate types, in this case reversibly blockednucleotide triphosphates (rbNTPs) are simultaneously added to a SBSreaction. The rbNTPs compete for incorporation into the growing nucleicacid strand during template directed extension of a primer. It iscontemplated that competitive extension in the presence of a sufficientvariety of nucleotide types to complement all of the nucleotide types inthe template nucleic acid improves fidelity of incorporation as comparedto adding nucleotides one at a time to a sequencing reaction. The fourrbNTP types possess a 3′-terminator that comprises, on the sample 3′ribose position, both alkoxy and azido functionalities which isremovable by cleavage with a phosphine reagent, thereby creating anucleotide that is reversibly blocked and once again functional forfurther elongation (i.e., fully functional or ff). Fully functionalnucleotides, ffNTPs, are commercially available from 11lumina, Inc. andare exemplary of reversibly blocked nucleotides, or rbNTPs. In preferredembodiments, three of the four rbNTPs comprise fluorescent labelsattached via linkers. The linkers may comprise one or more cleavagegroups, or no cleavage groups. For example, a linker attaching one ormore rbNTPs to a fluorophore may comprise an azide and/or an alkoxygroup, for example on the same carbon, such that the linkers may becleaved after each incorporation cycle by means of a phosphine reagentas previously referenced, thereby releasing the fluorescent moiety forfurther sequence elongation.

For example, the initial rbNTP thymine, (rbTTP) may be fluorescentlylabeled via a linker wherein the linker comprises an azide/alkoxycleavage site. Another initially fluorescently labeled rbNTP, forexample adenine or rbATP, comprises a linker that in addition to thealkoxy/azide group further comprises a second cleavage site like adisulfide group located between, for example, the alkoxy/azide group andthe fluorescent label. The fluorescent label associated with rbATP maybe the same as the fluorescent label associated with rbTTP, or it may bea similar fluorescent label in that they share similar excitation andemission spectral characteristics. A third rbNTP, for example cytosineor rbCTP, comprises a hapten moiety, such as a biotin, at the terminusof an alkoxy/azide containing linker. In this example the starting rbCTPis not fluorescently labeled and therefore does not fluoresce at a firstimaging event. However, subsequent treatment with a fluorescentlylabeled streptavidin causes binding of the streptavidin-fluorescentmoiety conjugate to the biotin moiety on the rbCTP conjugate and aftersuch treatment the locations where rbCTP was incorporated fluoresce whenexposed to the appropriate wavelength of light and the fluorescence isrecorded during the second imaging event. The fourth rbNTP, in this caseguanine or rbGTP lacks a fluorescent moiety and may or may not beconjugated to a linker, is considered a “dark” rbNTP and does notfluoresce, or has diminished or minimal fluorescence, at both imagingevents.

The aforementioned exemplary strategy can be further described accordingto the rbNTP construct, for example:

rbTTP-linker CS1-FM

rbATP-linker CS1-CS2-FM

rbCTP-linker-CS 1-B

rbGTP

wherein CS1 is a first cleavage site (e.g., azide/alkoxy), CS2 is asecond cleavage site (e.g., SS linkage), FM is a fluorescent moiety andB is biotin. It is contemplated that one of the cleavage sites isoptional. An optional cleavage site (e.g., two cleavage sites present ina linker) may provide additional functionality to a sequencing cycleincluding, but not limited to, cleavage of all fluorescent moieties in asubsequent cycle, alternate cleavage reactions in subsequent sequencingcycles and/or combining cleavage reactions in one or more sequencingcycles, or combinations thereof.

An exemplary detection scheme for a sequencing cycle for real timeanalysis of sequence by synthesis nucleotide incorporation utilizing theaforementioned strategy comprises two imaging event and in particularembodiments no more than two imaging events. The conjugated rbNTPs,rbTTP, rbATP and rbCTP and unconjugated (or perhaps conjugated to linkeronly) rbGTP are added simultaneously at the beginning of a sequencingcycle. Light of excitation wavelength for the fluorescent moiety isapplied to the sequencing reaction and a first image (image 1) isrecorded. The first image records fluorescence (1) for rbATP and rbTTPincorporations, but no fluorescence or minimal fluorescence for rbCTP orrbGTP incorporation. Following the first imaging event, DTT for exampleis added to the reaction which cleaves CS2 (disulfide bond) in thelinker of rbATP thereby releasing the FM and transitioning rbATP fromdetectable (1) to undetectable (0) for the second imaging event. TherbATP cleavage and resulting fluorescent transition step provides forthe differentiation of rbATP from the other rbNTP incorporation eventsduring a sequencing cycle. Additionally, following the first imagingstep a streptavidin (SA)-FM is added to the reaction. The SA binds the Bof the rbCTP composition thereby transitioning rbCTP from undetectable(0) to detectable (1) and allowing for detection of locations whererbCTP was incorporated in the reaction and providing for differentiationof rbCTP incorporation events during a sequencing cycle. In thisexample, there are no transition changes for either rbTTP or rbGTP. Assuch, following the application of the exemplary DTT and the SA-FM asecond image of the sequencing cycle is taken which results influorescent signals for incorporations of rbTTP and rbCTP and nofluorescence for rbATP and rbGTP incorporations. Following the secondimage the fluorescence transitions, or lack thereof, are used todetermine what nucleotide was incorporated at which location in thesequence by synthesis reaction. Each subsequent cycle follows the samepattern of polymerase extension-image 1-chemical treatment-image 2-nextcycle until the sequencing run is complete. The cycle can optionallyinclude a nucleotide determination step. Additionally or alternatively,determination of nucleotides or the sequence of nucleotides can occurafter one or more cycles are complete. Other steps can also be includedper cycle including, but not limited to, deblocking, washing and/oradditional steps used in sequence-by-synthesis methods known in the art.

It is contemplated that any number of potential cleavage sites and theircleavage compounds may be utilized in the aforementioned strategy, andthose mentioned are by way of example only. For example, reducing agentsbesides DTT (e.g., TCEP, BME, etc.) or reagents that participate inthiol-disulfide exchange reactions can be used for releasing afluorescent moiety as described above. Further, hapten binding partnersbesides biotin-streptavidin (e.g., digoxigenin, dinitrophenol andantibodies thereto) can also be utilized. Further, any one or morefluorescent moieties may be utilized. However if two or more are used itis preferable that they have the same or similar absorption and emissionspectra. Preferred embodiments utilize one fluorescent moiety fordetection of all incorporated nucleotides, or one optical filter thatdetects emission from a plurality of fluorescent moieties.

It is contemplated that the reaction reagents (i.e., cleavage reagents,labeling reagents etc.) added between the imaging events can be providedseparately, for example sequentially or combined and added as onecomplete reagent (e.g., a master mix comprising all necessary chemicalsto complete cleavage, labeling, etc.). Preferred embodiments compriseaddition of a complete reagent solution or master mix between theimaging steps.

In another exemplary embodiment, a second strategy for detecting anddetermining nucleotide incorporation in a sequencing reaction using onefluorescent dye (or two dyes of same or similar excitation/emissionspectra) and two imaging events is exemplified by the detection tableand grid shown in FIG. 7.

For the second strategy, as exemplified in the first, all four fullyfunctional nucleotide triphosphate (rbNTPs) compositions aresimultaneously added to a SBS reaction. The rbNTPs compete forincorporation into the growing nucleic acid strand. The rbNTPs possess a3′-terminator that comprises both alkoxy and azido functionalities whichare removable by cleavage with a phosphine reagent thereby creating anucleotide that is once again functional for further elongation. Inpreferred embodiments, three of the four rbNTPs comprise fluorescentlabels attached via linkers. The linkers may comprise one or morecleavage sites. For example, a linker attaching one or more rbNTPs to afluorophore may comprise an azide and/or an alkoxy group, for example onthe same carbon, such that the linkers may be cleaved after eachincorporation cycle by means of a phosphine reagent thereby releasingthe fluorescent moiety for further sequence elongation.

In the second strategy, the initial pool of rbNTP thymine comprises amixture of rbTTP molecules. For example, a pool of rbTTP comprises a 2:1ratio of a fluorescently labeled rbTTP (i.e., via a linker) andnon-fluorescently labeled rbTTP (i.e., dark rbTTP). It is contemplatedthat any ratio of fluorescent:non-fluorescent rbNTP, can be used. Forexample a 2:1, 1:0.5, 0.5:1, and 1:2 ratios would also work, thedifference of which would change the image intensity output withoutchanging the ability to detect and differentiate nucleotideincorporation. A fluorescently labeled rbATP, an unlabeled or dark rbGTPand a biotin labeled rbCTP complete the nucleotide mix. A subsequenttreatment with a fluorescently labeled streptavidin causes binding ofthe streptavidin-fluorescent moiety to the biotin moiety on the rbCTPconjugate and after such treatment the locations where rbCTP wasincorporated fluoresce when exposed to the appropriate wavelength oflight and the fluorescence is recorded during the second imaging event.

The aforementioned exemplary strategy can comprise the rbNTP constructs:

rbTTP-linker FM/rbTTP-dark

rbATP-linker-FM

rbCTP-linker-B

rbGTP-dark

An exemplary detection scheme for a sequencing cycle for real timeanalysis of sequence by synthesis nucleotide incorporation utilizing theaforementioned strategy comprises two imaging events and in particularembodiments no more than two imaging events. All four of the rbNTP typesare added simultaneously at the beginning of a sequencing cycle. Lightof excitation wavelength for the fluorescent moiety is applied to thesequencing reaction and a first image (image 1) is recorded. The firstimage includes fluorescence (1) for rbATP and rbTTP (at 50% fluorescenceintensity) incorporations, but no fluorescence for rbCTP, rbGTP and 1/2of the rbTTP incorporations. Following the first imaging step, astreptavidin labeled fluorophore SA-FM is added to the reaction. The SAbinds the B of the rbCTP composition thereby transitioning rbCTP fromundetectable (0) to detectable (1) during the second imaging event andallowing for detection of locations where rbCTP was incorporated in thereaction and providing for differentiation of rbCTP incorporation eventsduring a sequencing cycle. In this example, there are no transitionchanges for rbTTP, rbATP or rbGTP. Following the second image thefluorescence transitions, or lack thereof, are used to determine whatnucleotide was incorporated at which location in the sequence bysynthesis reaction and the sequence of interest is identified. Eachsubsequent cycle follows the same pattern of polymerase extension-image1-treatment-image 2-next cycle until the total sequencing of the desiredtarget is complete. The cycle can optionally include a nucleotidedetermination step. Additionally or alternatively, determination ofnucleotides or the sequence of nucleotides can occur after one or morecycles are complete. Other steps can also be included per cycleincluding, but not limited to, deblocking, washing and/or additionalsteps used in sequence-by-synthesis methods known in the art.

In another embodiment, a third strategy for detecting and determiningnucleotide incorporation in a sequencing reaction using one fluorescentdye (or two dyes of same or similar excitation/emission spectra) and twoimaging steps is exemplified by the detection table and grid shown inFIG. 8.

As exemplified in the first and second, all four fully functionalnucleotide triphosphate (rbNTPs) compositions are simultaneously addedto a SBS reaction. The rbNTPs compete for incorporation into the growingnucleic acid strand. The rbNTPs possess a 3′-terminator that isremovable, thereby creating a nucleotide that is once again functionalfor further elongation. The third strategy differs from previousexemplary strategies by incorporating, for example, by conjugating arbNTP to a branched linker. In preferred embodiments, two of the fourrbNTPs comprise fluorescent labels attached via linkers. The linkers maycomprise one or more cleavage sites. For example, a linker attaching oneor more rbNTPs to a fluorophore may comprise an azide and/or an alkoxygroup, for example on the same carbon, such that the linkers may becleaved after each incorporation cycle by means of a phosphine reagentas previously described, thereby releasing the fluorescent moiety forfurther sequence elongation.

In the third exemplary strategy, rbATP and rbCTP complexes comprisebranched linkers.

For example, rbATP comprises a branched linker wherein one branchterminates with a fluorescent moiety and a second branch terminates in abiotin. In this example, the rbCTP is also complexed with a branchedlinker and each of two branches terminates in a biotin. The rbCTP inthis example is initially unlabeled. A fluorescently labeled rbTTP andan unlabeled or dark rbGTP complete the nucleotide mix. A subsequenttreatment with a fluorescently labeled streptavidin causes very strongbinding of the streptavidin-dye to the biotin moieties on the C and Anucleotides and after such treatment the locations where rbCTP and rbATPwere incorporated fluoresce when exposed to the appropriate wavelengthof light and the fluorescence resulting from the B-SA interaction isrecorded during the second imaging step.

The aforementioned exemplary strategy as such can comprise:

rbATP-branched linker FM and B

rbTTP-FM

rbCTP-branched linker-(B)²

rbGTP-dark

An exemplary detection scheme for a sequencing cycle for real timeanalysis of sequence by synthesis nucleotide incorporation utilizing theaforementioned strategy comprises two imaging steps and in particularembodiments no more than two imaging events. All the rbNTPs are addedsimultaneously at the beginning of a sequencing cycle. Light ofexcitation wavelength for the fluorescent moiety is applied to thesequencing reaction and a first image (image 1) is recorded. The firstimage includes fluorescence (1) for rbATP and rbTTP incorporations, butno fluorescence (0) for rbCTP and rbGTP incorporations. Following thefirst imaging step, a streptavidin labeled fluorophore SA-FM is added tothe reaction. The SA binds the two biotins (B²) of the rbCTP conjugatethereby transitioning rbCTP from undetectable (0) to detectable (1) andthe B on the bifurcated linker of rbATP thereby effectively increasingthe fluorescence (2) of rbATP incorporation from image 1 and allowingfor detection of locations where rbCTP was incorporated, anddifferentiating rbATP incorporation, in the growing nucleic acid strand.In this example, there are no transition changes for rbTTP or rbGTP.Following the second image the fluorescence transitions, or lackthereof, are used to determine what nucleotide was incorporated at whichlocation in the sequence by synthesis reaction and the sequence ofinterest is identified.

Each subsequent cycle follows the same pattern of polymeraseextension-image 1-treatment-image 2-next cycle until sequencing of thedesired target is complete. The cycle can optionally include anucleotide determination step. Additionally or alternatively,determination of nucleotides or the sequence of nucleotides can occurafter one or more cycles are complete. Other steps can also be includedper cycle including, but not limited to deblocking, washing and/or othersteps used in sequence-by-synthesis methods known in the art.

In another embodiment, a fourth exemplary strategy for detecting anddetermining nucleotide incorporation in a sequencing reaction uses onefluorescent dye (or two dyes of same or similar excitation/emissionspectra) and only one imaging step as exemplified by the detection tableand grid shown in FIG. 9.

The aforementioned exemplary embodiment can comprise only one dye, ortwo dyes of the same or similar excitation/emission spectra wherein thedye concentration changes for each of the three labeled rbNTPs. A darkstate denotes the incorporation of, in this case, rbGTP based on theinterpretation of fluorescence measurement from the three fluorescentlylabeled rbNTPs.

The aforementioned exemplary strategy as such can comprise:

rbATP-FM (0.33× concentration)

rbTTP-FM (1.0×concentration)

rbCTP-FM (0.66×concentration)

rbGTP-dark

An alternative embodiment comprising one dye (or two dyes of the same orsimilar excitation/emission spectra) and one image event is illustratedin the detection table and grid shown in FIG. 10.

The aforementioned exemplary strategy as such can comprise:

rbATP-FM (0.50× concentration)

rbTTP-FM (1.0× concentration)

rbCTP-FM (0.75× concentration)

rbGTP-FM (0.25× concentration)

The aforementioned exemplary embodiment can comprise one dye or two dyesof similar excitation/emission spectra such that each of the four rbNTPsare labelled with different dye concentrations. In embodiments whereineach of four different rbNTPs are attached to a different concentrationof one dye (or two dyes of similar excitation/emission spectra) only oneimage is taken per cycle to determine nucleotide incorporation. Anexemplary sequence cycle practicing one dye/one image event methodswould be polymerase extension-image 1-next cycle.

An exemplary detection scheme for a sequencing cycle for one dye/oneimage event sequence by synthesis nucleotide incorporation utilizing theaforementioned strategies comprises one imaging step. All the rbNTPs areadded simultaneously at the beginning of a sequencing cycle. Light ofexcitation wavelength for the fluorescent moiety is applied to thesequencing reaction and a first image (image 1) is recorded. Followingthe first imaging step, the next cycle of reagent addition, polymeraseextension and image acquisition are carried out until the desired numberof cycles are completed. Following the first image the fluorescenceintensity can be correlated to the different dye concentrations are usedto determine what nucleotide was incorporated at which location in thesequence by synthesis reaction and the sequence of interest isidentified. Each subsequent cycle follows the same pattern of polymeraseextension-image 1-next cycle until sequencing of the desired target iscomplete. The cycle can optionally include a nucleotide determinationstep. Additionally or alternatively, determination of nucleotides or thesequence of nucleotides can occur after one or more cycles are complete.Other steps can also be included per cycle including, but not limited todeblocking, washing and/or other steps used in sequence-by-synthesismethods known in the art.

In embodiments practicing one dye/one image event sequencing, dyeconcentrations are provided that allow for the differentiation ofincorporation of the labelled and/or unlabelled nucleotides. Further,when practicing a sequencing reaction of one dye/one image asexemplified above, additional chemical treatment is not necessary aspreviously described for embodiments for one dye/two image sequenceingstrategies.

In another exemplary embodiment, an additional strategy for detectingand determining nucleotide incorporation in a sequencing reactioncomprises using two fluorescent dyes of different excitation andemission spectra and either 1) one imaging event comprising two emissionspectra or 2) two sequential imaging events.

For purposes of example FIG. 3A shows two exemplary dyes, a dye thatemits at around 590 max (DEG527) and a dye that emits at around 720 max(Dy681). For purposes of example, the following rbNTP-dye conjugationsare made:

rbATP-DEG527

rbCTP-Dy681

rbTTP-DEG527/Dy681

rbGTP-dark

As such, the percentage of each incorporated nucleotide conjugated to aparticular fluorophore. In this example the conjugations are:

rbNTP Dy681 DEG527 Dark rbATP 100% rbCTP 100% rbTTP  50%  50% rbGTP 100%

As an example, following standard SBS protocols, all four of nucleotidesare added simultaneously to a SBS reaction. The rbNTPs compete forincorporation in the growing nucleic acid strand. As previouslydescribed, the rbNTPs possess a 3′ terminator that is removable bycleavage for further elongation. Following incubation allowing for theincorporation of the appropriate nucleotide into the growing nucleicacid strand, the reaction is exposed to the appropriate wavelength oflight depending on which imaging, simultaneous or sequential, isdesired. For example, the reaction can be exposed simultaneously to theexcitation wavelength of both fluorescent dyes (in this example, DEG527is excited at approximately 532 nm and Dy681 is excited at approximately660 nm) thereby causing simultaneous emission of the two fluorescentdyes, emission of which can be detected simultaneously by two differentdetection filters and imaging optics. In such a simultaneous systemwherein only 1 imaging event is performed for two different detectionchannels simultaneously, the image states for each detection channelwould be:

Image 1-green Image 1-red A 1 0 C 0 1 T 0.5 0.5 G 0 0

Alternatively, after incorporation of the appropriate labeled nucleotideinto the growing nucleic acid strand the two fluorescent dyes can beexcited in a step by step manner, such as first exciting one fluorophorefollowed by a first imaging event and then exciting the secondfluorophore followed by a second imaging event. In such a step by stepimaging system two imaging events are performed and the detection tablewould be, for example if DEG527 is first excited followed by Dy681(e.g., vice versa if red fluorescence emission is first imaged followedby green fluorescence) the image states for each image event would be:

Image 1-green Image 2-red A 1 0 C 0 1 T 0.5 0.5 G 0 0

In either case, the incorporation of an A would be detected at a certainintensity in the green channel only, the incorporation of a C would bedetected at a certain intensity in the red channel only, theincorporation of a T would be detected in both the green and redchannels at half the intensity of the A and C, and G would be minimallyor not detected in either green or red channels (FIG. 3B). Following theimaging step or steps, the fluorescent dye and the 3′ terminator arecleaved and the next sequencing cycle is performed.

This example is not limited to any particular two dyes or conjugatecombinations and any two dyes of different fluorescence spectra could beused in a two dye sequencing system, in any combination of rbNTP-dyeconjugate combination. For example, the dyes depicted in the aboveexample emitted in the red and green wavelengths. However, the methodsand systems are not limited by the excitation or emission wavelengths(e.g., fluorescence spectra) of any particular dye, as such any dyesthat differ in fluorescence spectra can be potentially useful. Further,the example describes certain rbNTP-dye conjugates; however conjugatesare not limited to those particular combinations. For example, any ofthree rbNTPs could be potentially conjugated to any of the listed dyes(one nucleotide remaining unconjugated or dark). Examples of dyes andderivatives thereof useful in embodiments described herein include, butare not limited to, those described below.

Additionally, the one or more nucleotide type conjugates described inthe above strategy could further comprise one or more linkers asdescribed in alternative embodiments and strategies. As such, one ormore chemical or modifying reactions could be incorporated into asequencing reaction in combination with the strategy wherein two dyes ofdifferent fluorescence spectra are conjugated to different nucleotidetypes. Therefore, the nucleotide type conjugates in this example couldbe further modified in any number of ways as described herein withoutdetracting from the embodiment wherein two dyes of differentfluorescence spectra can be employed to determine the sequence of anucleic acid.

In another exemplary embodiment, an additional strategy for detectingand determining nucleotide incorporation in a sequencing reactioncomprises using two fluorescent dye sets wherein each set of dyescomprises two dyes of similar fluorescence emission spectra or withemission λ_(max) off-set by up to, for example, 100 nm, wherein one ofthe two dyes emits at a detectably higher intensity than the other dyein the set, and wherein the two fluorescent dye sets differ influorescence emission spectra. In preferred embodiments, the dye in adye set that is detectably higher intensity than the other dye in theset is at least 0.5×, at least 0.75×, at least 1×, at least 2× asintense as the lower intensity dye. When practicing two fluorescent dyesets as described herein, sequence determination can be via one imagingevent or two imaging events.

For purposes of example FIG. 4A shows two exemplary dye sets; bothDEG527 and Atto532 can be detected together (fluorescence emission fromapproximately λ_(max) 555-595 nm) and Dy681 and 507181 can be detectedtogether (fluorescence emission from approximately λ_(max) 670-715 nm).For purposes of example, the following rbNTP-dye conjugations are made:

rbATP-DEG527

rbCTP-Dy681

rbTTP-Atto532/S07181

rbGTP-dark

As such, the percentage of each incorporated nucleotide conjugated to aparticular fluorophore in this example is:

rbNTP S07181 Dy681 Atto532 DEG527 Dark rbATP 100% rbCTP 100% rbTTP 50%50% rbGTP 100%

As an example, following standard SBS protocols, all four of nucleotidesare added simultaneously to a SBS reaction. The rbNTPs compete forincorporation in the growing nucleic acid strand. As previouslydescribed, the rbNTPs possess a 3′ terminator that is removable bycleavage for further elongation. Following incubation allowing for theincorporation of the appropriate nucleotide into the growing nucleicacid strand, the reaction is exposed to a first wavelength of light, afirst imaging event is performed, then the reaction is exposed to thesecond wavelength of light and a second imaging event is performed.

For example, after incorporation of the appropriate labeled nucleotideinto the growing nucleic acid strand the two sets of fluorescent dyescan be excited in a step by step manner, such as first exciting one setof fluorophores followed by a first imaging event and then exciting thesecond set of fluorophores followed by a second imaging event. As anexample, if DEG527/Atto532 is first excited followed by Dy681/SO7181(e.g., vice versa if red fluorescence emission is first imaged followedby green fluorescence) the image states for each image event would be:

Image 1-green Image 2-red A 1 0 C 0 1 T >1 >1 G 0 0

The image states for T are listed as >1 for each image event. The >1designation assumes that the higher intensity dye is at least greater inintensity than that of the lower intensity dye in the dye pair.

Alternatively, the reaction can be exposed simultaneously to theexcitation wavelength of both fluorescent dyes thereby causingsimultaneous emission of the two fluorescent dyes, emission of which canbe detected simultaneously by two different detection filters andimaging optics. In such a simultaneous system wherein only 1 imagingevent is performed for two different detection channels simultaneously,the image states for each detection channel would be:

Image 1-green Image 1-red A 1 0 C 0 1 T >1 >1 G 0 0

In either case, the incorporation of an A would be detected at a certainintensity in the green channel only and the incorporation of a C wouldbe detected at a certain intensity in the red channel only. However, dueto the increased intensity of the dyes that are conjugated to rbTTPcompared to the lower intensity dyes conjugated to the rbATP and rbCTP,it is contemplated that the incorporation of a T would be detected inboth the green and red channels at equal to or greater intensity of theA and C. Once again, in this example incorporation of G would beminimally or not detected in either green or red channels.

FIG. 4B shows a cloud heat map demonstrating the detection ofincorporated rbTTP as compared to rbCTP and rbATP when practicing thedescribed two dye sets, wherein one dye is of higher intensity than theother dye in the set. Following the imaging steps, the fluorescent dyeand the 3′ terminator are cleaved and the next sequencing cycle isperformed.

Additionally, the one or more nucleotide type conjugates described inthis example could further comprise one or more linkers as described inalternative embodiments. As such, one or more chemical or modifyingreactions could be incorporated into a sequencing reaction incombination with the strategy wherein two dye sets of different emissionspectra are conjugated to different nucleotide types. Therefore, thenucleotide type conjugates in this example could be further modified inany number of ways as described herein without detracting from theembodiment wherein two dye sets of different emission spectra can beemployed to determine the sequence of a nucleic acid.

Additionally, this example is not limited to any particular two dye setsor conjugate combinations and any two dye sets of different emissionspectra could be used, in any combination of rbNTP-dye conjugatecombination while following the strategy for conjugation as disclosedherein (e.g., two nucleotide types are conjugated to different lowerintensity dyes and one nucleotide type is conjugated to two higherintensity dyes). The example describing the use of two dye sets forsequencing methods is not limited to any particular sets of two dyes andany dye sets of different fluorescence spectra could be used in thesequencing system as described herein. Additional dye sets comprisethose that have emission max off-set of at least 60 nm, at least 70 nm,at least 80 nm, at least 90 nm, at least 100 nm, preferably at least 100nm. Examples of dye sets include, but are not limited to, Atto465, 488,495/Atto514, 520, 532, 550, 565; Atto 520, 532, 550/Atto565, 590, 594,Rho11, Rho 12, Rho 13; Atto 647, 655, 665/Atto 680, 700, 725; Alexa 647,660, Cy5/Alexa 680, 700, Cy5.5; Alexa532, Cy3/Alexa555, 556, 578, 590,Cy3.5; Alexa 488/Alexa532, 555, 556, 578; Dy 647, 648, 649, 650, 651,652, 654/Dy675, 676, 677, 678, 679, 680, 681, 682, 700, 701, 703, 704;Dy490, 495, 505/Dy530, 547, 548, 549, 550, 554,555, 556, 560; Dy530,547, 548, 549, 550, 554,555, 556, 560/Dy590, 591, 594, 605, 610, 615.

The above strategies are exemplary in nature, describe only several ofmany potential strategies and serve to provide a guide underlying theinnovative methods and compositions disclosed herein for utilizing onefluorescent moiety, or a plurality of fluorescent moieties of the sameor similar excitation/emission spectra, for sequencing a nucleic acid. Askilled artisan will understand that the different strategies provide aguide for creating additional strategies using one fluorescent moiety,or a plurality of fluorescent moieties of the same or similarexcitation/emission spectra, for sequencing a nucleic acid, and still bewithin the scope of the methods as disclosed herein.

In one embodiment, a rbNTP conjugate as described herein comprisesdetection moiety(s)

linker(s)

base

wherein a detection moiety is one or more of a fluorescent moiety, ahapten or combinations thereof, wherein a linker is one or more of aspacer linker, a linker with one or more cleavage sites, or combinationsthereof, wherein a base is one of three modified nucleotides (e.g.,rbNTPs) wherein X is a monophosphate, diphosphate or triphosphate andwherein R₁ is —H, —OH, —OCH₂N₃ or any group which can be transformedinto an —OH, including carbonyl covalently bonded to the 3′ carbon.

In some embodiments, a detection moiety is a fluorescent moiety. In someembodiments, a detection moiety is a hapten that is detectable via abinding partner-fluorescent moiety conjugate. In some embodiments, arbNTP conjugate comprises one or both of a fluorescent moiety and ahapten linked to a rbNTP via one or more linkers. In some embodiments ahapten is a biotin, digoxigenin (DIG) or dinitrophenol (DNP). In someembodiments, a hapten is detected by a binding partner-fluorescentmoiety conjugate. In some embodiments, a binding partner is a smallmolecule or an antibody or fragment thereof, for example streptavidin,anti-DIG or anti DNP.

Exemplary fluorescent moieties, or derivatives thereof, for use asfluorescent moieties in accordance with disclosed embodiments include,but are not limited to, fluorescein and fluorescein derivatives such ascarboxyfluorescein, tetrachlorofluorescein, hexachlorofluorescein,carboxynapthofluorescein, fluorescein isothiocyanate, NHS-fluorescein,iodoacetamidofluorescein, fluorescein maleimide, SAMSA-fluorescein,fluorescein thiosemicarbazide, carbohydrazinomethylthioacetyl-aminofluorescein, rhodamine and rhodamine derivatives such as TRITC, TMR,lissamine rhodamine, Texas Red, rhodamine B, rhodamine 6G, rhodamine 10,NHS-rhodamine, TMR-iodoacetamide, lissamine rhodamine B sulfonylchloride, lissamine rhodamine B sulfonyl hydrazine, Texas Red sulfonylchloride, Texas Red hydrazide, coumarin and coumarin derivatives such asAMCA, AMCA-NHS, AMCA-sulfo-NHS,AMCA-HPDP, DCIA, AMCE-hydrazide, BODIPYand derivatives such as BODIPY FL C3-SE, BODIPY 530/550 C3, BODIPY530/550 C3-SE, BODIPY 530/550 C3 hydrazide, BODIPY 493/503 C3 hydrazide,BODIPY FL C3 hydrazide, BODIPY FL IA, BODIPY 530/551 IA, Br-BODIPY493/503, Cascade Blue and derivatives such as Cascade Blue acetyl azide,Cascade Blue cadaverine, Cascade Blue ethylenediamine, Cascade Bluehydrazide, Lucifer Yellow and derivatives such as Lucifer Yellowiodoacetamide, Lucifer Yellow CH, cyanine and derivatives such asindolium based cyanine dyes, benzo-indolium based cyanine dyes, pyridiumbased cyanine dyes, thiozolium based cyanine dyes, quinolinium basedcyanine dyes, imidazolium based cyanine dyes, Cy 3, Cy5, lanthanidechelates and derivatives such as BCPDA, TBP, TMT, BHHCT, BCOT, Europiumchelates, Terbium chelates, Alexa Fluor dyes, DyLight dyes, Atto dyes,LightCycler Red dyes, CAL Flour dyes, JOE and derivatives thereof,Oregon Green dyes, WellRED dyes, IRD dyes, phycoerythrin and phycobilindyes, Malacite green, stilbene, DEG dyes (for example as those describedin US2010/0009353, incorporated herein by reference in its entirety), NRdyes, near-infrared dyes and others known in the art such as thosedescribed in Haugland, Molecular Probes Handbook, (Eugene, Oreg.) 6thEdition; The Synthegen catalog (Houston, Tex.), Lakowicz, Principles ofFluorescence Spectroscopy, 2nd Ed., Plenum Press New York (1999),Hermanson, Bioconjugate Techniques, 2^(nd) Edition, US2010/0009353 or WO98/59066, each of which is incorporated by reference in theirentireties.

In some embodiments, a detection moiety is conjugated to a rbNTP via alinker. In some embodiments a rbNTP conjugate comprises one or more thanone linker. In some embodiments, a linker is a spacer linker that isconjugated on one end to a rbNTP and on the other to a detection moiety.In some embodiments, a spacer linker comprises one or more cleavagegroups. Conversely, in some embodiments a spacer linker contains nocleavage group. In one embodiment, a spacer linker (e.g., with orwithout a cleavage group) is a polyethylene glycol (PEG) molecule orconcatamers thereof. For example, in some embodiments, a spacer linkercomprises concatamers of at least two, of at least three, of at leastfour, of at least five, of at least six, of at least seven, of at leasteight, of at least ten or of at least twelve PEG molecules.

In preferred embodiments, spacer linkers used to conjugate a rbNTP to adetection moiety, for example a fluorescent moiety or a hapten, compriseat least four to twelve concatamers of PEG (i.e., PEG4, PEG 8, PEG 12).In some embodiments, a spacer linker comprises2-{2-[3-(2-amino-ethylcarbomyl)-phenoxyl-1-azido-ethoxy}-ethoxy-aceticacid. In some embodiments, the spacer linker comprising2-{2-[3-(2-amino-ethylcarbomyl)-phenoxyl-1-azido-ethoxy}-ethoxy-aceticacid comprises one or more cleavage groups. In some embodiments, a rbNTPis attached to two spacer linkers (for example, separate linkers of abifurcated linker construct), which may be the same or different, eachof which terminates in a detection moiety. In some embodiments, twospacer linkers comprise a PEG and a2-{2-[3-(2-amino-ethylcarbomyl)-phenoxyl-1-azido-ethoxy}-ethoxy-aceticacid linker, one or both of which may or may not comprise one or morecleavage groups, terminating in a detection moiety. In some embodiments,two spacer linkers may be two PEG linkers which may be of equal orunequal lengths (e.g., one PEG4 and the other PEG12), each of the PEGlinkers terminating in a detection moiety, further with or without acleavage group.

Examples of linkers can be found at, for example U.S. Pat. Nos.7,816,503, 7,771,973, and patent application 2010/00317531 (each ofwhich are incorporated herein by reference in their entireties). Methodsand compositions as described herein are not limited by any particularspacer linker and alternatives will be readily apparent to a skilledartisan and are considered within the scope of the present disclosure.

In some embodiments, a spacer linker comprises one or more cleavagegroups. Cleavage groups for use in methods as described herein mayinclude, but are not limited to disulfide groups, acid labile groups,Sieber groups, indole groups, t-butyl Sieber groups, electrophilicallycleavable groups, nucleophilically cleavable groups, photocleavablegroups, cleavage groups that cleave under reductive conditions,oxidative conditions, cleavage via use of safety-catch groups, cleavageby elimination mechanism and metal assisted cleavable groups. As usedherein, the term “cleavable linker” is considered equivalent to a spacerlinker that comprises one or more cleavage groups. A discussion oflinkers can be found at, for example, Guiller et al, 2000, Chem. Rev.100:2091-2157 and as provided in U.S. Pat. No. 7,771,973, both of whichare incorporated herein by reference in their entireties. Methods andcompositions as described herein are not limited by any particularcleavage group and alternatives will be readily apparent to a skilledartisan and are considered within the scope of the present disclosure.

In some embodiments, reversibly blocked modified nucleotides asdescribed herein are attached to a small molecule via a linker. In someembodiments, a linker comprises one or more cleavable groups and may bereferred to as a cleavable linker. Cleavable groups include, but are notlimited to, disulfide, diol, diazo, ester, sulfone azide, alyl and silylether, azide and alkoxy groups. In preferred embodiments, one or more ofan azide, an alkoxy and a disulfide group is associated with reversiblyblocked nucleotide (rbNTP) with another molecule, for example a haptenor a detection moiety, or both, for use in methods as described herein.Incorporation of a disulfide bond into a linker as described herein canbe accomplished in a number of ways, for example as provided here, asfound in U.S. Pat. No. 7,771,973, or as described in Hermanson,Bioconjugate Techniques, Second Edition, Academic Press (incorporatedherein by reference in their entireties).

In some embodiments, a composition comprising a cleavage agent is addedto a sequencing reaction to cleave a cleavage group in a spacer linkerof a rbNTP conjugate. The cleavage agent added is dependent on thecleavage group present. For example, cleavage of disulfide bonds orother reductive cleavage groups is accomplished by a reducing agent.Reduction of a disulfide bond results in the release of the rbNTP fromthe linked molecule, for example a hapten, hapten conjugate and/ordetection moiety such as a fluorescent moiety. Reducing agents useful inpracticing embodiments as described herein include, but are not limitedto, phosphine compounds, water soluble phosphines, nitrogen containingphosphines and salts and derivatives thereof, dithioerythritol (DTE),dithiothreitol (DTT) (cis and trans isomers, respectively, of2,3-dihydroxy-1,4-dithiolbutane), 2-mercaptoethanol or β-mercaptoethanol(BME), 2-mercaptoethanol or aminoethanethiol, glutathione, thioglycolateor thioglycolic acid, 2,3-dimercaptopropanol and tris(2-carboxyethyl)phosphine (TCEP), tris(hydroxymethyl)phosphine (THP) andβ-[tris(hydroxymethyl)phosphine] propionic acid (THPP). In someembodiments, a reducing agent used for cleaving a disulphide bond in alinker as described herein is DTT. In some embodiments, theconcentration of a reducing reagent, for example DTT, utilized forcleaving a disulfide bond is at least 1 to 1000 mM, at least 20 to 800mM, at least 40 to 500 mM, and preferably at least 50 to 200 mM. In someembodiments, a reducing agent used for cleaving a disulphide bond in alinker as described herein is a phosphine reagent, a water solublephosphine reagent, a nitrogen containing phosphine reagent and salts andderivatives thereof. Exemplary phosphine reagents include, but are notlimited to, TCEP, THP and those disclosed in US patent publication2009/0325172 (incorporated herein by reference in its entirety) such astriaryl phosphines, trialkyl phosphines, sulfonate containing andcarboxylate containing phosphines and derivatized water solublephosphines. In some embodiments, the concentration of a phosphineutilized for cleaving a disulfide bond is at least 0.5-500 mM, at least5 to 50 mM, and preferably at least 10 to 40 mM. Methods andcompositions as described herein are not limited by any particularcleavage group and alternatives will be readily apparent to a skilledartisan and are considered within the scope of the present disclosure.

In some embodiments, a linker as described herein, which may or may notcomprise a cleavage site, links a rbNTP to a fluorescent moiety and afluorescence transition pattern for detecting incorporation of thenucleotide into a SBS reaction is realized by the addition of a quencherdye into a sequencing cycle. For example, a rbNTP conjugated to afluorescent moiety via a linker (wherein the linker may or may notcomprise a cleavage site) is added to a sequencing reaction. A firstimage is recorded thereby establishing a first detection pattern. Duringan intermediate reaction step, a quencher dye is added to the reaction(e.g., in lieu of a FRET partner removed from the reaction via acleavage step) wherein the quencher dye sufficiently quenches thefluorescence of the aforementioned fluorescent moiety resulting in adetectable fluorescence change pattern (e.g., fluorescence to non orminimal fluorescence) upon a subsequent imaging step for thatnucleotide. This embodiment is an alternative to a FRET donor/acceptorsystem as described herein, wherein the combination of two dyes resultsin fluorescence and the removal of one of the dyes, for example by acleavage reaction, results in loss of fluorescence.

Quenching dyes as envisioned herein include, but are not limited to,those substances that absorb the excitation energy of a fluorophore,effectively quenching fluorescence of the target fluorophore, howeverare not typically fluorescent themselves. Examples of quencher dyesinclude, but are not limited to dark quenchers such as DABCYL (absorbsin the green spectrum), Iowa black FQ (absorbs in the green-yellowspectrum), Iowa black RQ (absorbs in the orange-red spectrum), IRDyeQC-1 (absorbs in the 500-900 nm range) and Black Hole Quencher™ dyes(absorbs in the 500-700 nm range). For example, DABCYL is oftentimesused to quench fluorescein fluorescence and Black Hole Quencher™ dyesare utilized to quench fluorescence from FAM, TET, HEX, JOE, TAMRA, ROXand CY dyes depending on the characteristics (e.g., absorbance maximum)of the particular Black Hole Quencher™. In additional embodiments, suchdark quenchers can be utilized in a FRET system, wherein the cleavage ofthe dark quencher during an intermediate step results in a fluorescencestate change from quenched fluorescence to fluorescence, therebyestablishing a detection pattern for incorporation of a nucleotide intoa SBS reaction cycle.

Use of dye quenching embodiments as described herein are contemplatedfor use in permutations and combinations for detecting incorporation ofa nucleotide into a SBS cycle as recognized by a skilled artisan. Forexample, a rbNTP may be linked to a fluorescent moiety wherein aquencher dye is utilized to determine nucleotide incorporation, a secondrbNTP may be linked to a biotin wherein addition of a SA-fluorescentmoiety is utilized to determine nucleotide incorporation and a third dyemay be linked to a fluorescent moiety wherein a cleavage reaction isutilized to determine nucleotide incorporation. Methods as describedherein are not limited by which nucleotide is conjugated to whichparticular detection system, other than their combination allows for thedetermination of incorporation of nucleotides into a sequencingreaction.

In some embodiments, the fluorescent detection moiety is modified toprovide a detectable fluorescence difference between image 1 and image2. For example, a fluorescent moiety which is attached either directlyor indirectly to a rbNTP can be imaged during a first image event.Between the first and second image event a chemical, small molecule,etc. may be added to the sequencing reaction such that the structure ofthe fluorophore is modified thereby rendering the fluorescent moietyundetectable or minimally detectable during the second imaging event.For example, a cleavage agent which targets one or more bonds and/orstructural entities of the fluorescent moiety may be added which maydestroy the fluorescent nature of the fluorescent moiety therebyallowing for the detection of image states indicative of theincorporation of the attached rbNTP. As such, modifications of thefluorescent moiety itself can provide for detectable changes in imagingstates which may be advantageous in methods as described herein.

In some embodiments of the present disclosure, a nucleotide type for usein a sequencing reaction is a rbNTP conjugate comprising a base, forexample a natural or a modified base. In preferred embodiments, a baseis a modified base. In preferred embodiments, a modified base comprisesthree phosphate groups off the sugar backbone, as such is atriphosphate, as denoted by NTP. In preferred embodiments, the modifiedbase is reversibly blocked wherein the NTP comprises a reversibleterminator 3′ blocking group which, once removed, allows for continuedextension in a sequence by synthesis sequencing reaction. In someembodiments, the 3′ blocking group comprises an azido and/or alkoxygroup and is removable by cleavage with a phosphine reagent. Suchnucleotides are termed “reversibly blocked” or “rb”, a type of which isa “fully functional” or “ff” NTP (commercially available at 11lumina,Inc.). Further discussion of rbNTPs is found at, for example, U.S. Pat.Nos. 7,816,503 and 7,771,903 and United States patent applicationpublication US2010/00317531 (each of which is incorporated herein byreference in its entirety)

Disclosed methods for nucleic acid detection find particular utilitywhen used in sequencing, for example sequencing by synthesis (SBS)technologies. Sequencing by synthesis generally comprises sequentialaddition of one or more fluorescently labeled nucleotides to a growingpolynucleotide chain in the 5′ to 3′ direction using a polymerase. Theextended polynucleotide chain is complementary to the nucleic acidtemplate affixed on the substrate (e.g., flowcell, chip, Slide, etc.),the target sequence. In some embodiments, the identity of anincorporated nucleotide in the extended chain is determined after twoimaging steps thereby providing real time incorporation sequence data.

Disclosed method for nucleic acid detection also find utility when usedin sequencing by ligation, sequencing by hybridization, and othersequencing technologies wherein “dark” nucleotide and/or orthogonalnucleotide modification schemes are employed.

Sequence by ligation is a sequencing method wherein a sequencing primeris elongated on a target sequence by ligating a probe comprising anucleotide type (e.g., A, T, C or G), wherein the probe ligated isindicative of the sequence of the subsequent nucleotide in a targetnucleotide string. Sequencing by ligation probes may comprise cleavagesites which can be cleaved following a ligation event so that anotherround probe addition, ligation, and nucleotide incorporationdetermination can be performed. An exemplary sequence by ligationmethodology is di-base encoding (e.g., color space sequencing) utilizedby Applied Biosystems' SOLiD™ sequencing system. Di-base encoding, or“color space” sequencing utilizes interrogation probes comprising 2probe specific bases (e.g., made up of all possible combinations of thefour different nucleotide types) followed by three degenerate bases andsix universal bases, wherein each of the interrogation probes is linkedto one of four different fluorescent dyes. The probes are added to asequencing reaction comprising a target and a sequencing primer and athermostable ligase ligates the di-base probe complementary to thosesequences adjacent to the sequencing primer as found on the template.Fluorescence is detected by four color imaging, the ligated probes arecleaved to remove the fluorescent dye and regenerate the 5′ phosphatefor additional rounds of ligation and detection. Each template base isinterrogated twice. Following several rounds of ligation and detectionof one sequencing primer, the synthetic strand is denatured, a newsequencing primer is added, and the process of ligation detection beginsanew. The di-coded fluorescent color space data bits are aligned,applied to a color space reference genome grid and sequence isdetermined (Voelkerding et al., 2009, Clin Chem 55:641-658; incorporatedherein by reference in its entirety).

The modified nucleotides disclosed herein could be utilized in sequenceby ligation technologies. For example, probes from a two base encodingscheme in which four dinucleotide sequences are associated with onecolor, for example AA, CC, GG and TT may be associated with a bluefluorescent dye, another four dinucleotide sequences are associated witha red dye, another four a green dye are detection is via a four colorimaging system could be modified as described herein. The incorporationof less than four dyes, for example one dye or two or more dyes ofsimilar excitation/emission while practicing chemical and/or enzymaticmanipulations would allow for fewer imaging events thus more simplifiedinstrument optics. For example, a probe comprising four dinucleotidesequences such as AA, CC, GG and TT, further comprising a number ordegenerate and/or universal nucleotides (optionally), could furthercomprise a linker containing a cleavage site (for example an azide oralkoxy cleavage site) linking the dinucleotide with a fluorescentmoiety. A probe comprising a second set of four dinucleotides, forexample TA, GC, CG and AT, further comprising a number or degenerateand/or universal nucleotides (optionally), could further comprise alinker containing two cleavage sites (the second cleavage site differentfrom the first, for example a SS linkage) linking the dinucleotide witha fluorescent moiety. A probe set comprising a third set of fourdinucleotides, for example CA, AC, GT and TG, further comprising anumber or degenerate and/or universal nucleotides (optionally), couldfurther comprise a linker containing a cleavage site linking thedinucleotide with a hapten moiety (for example biotin). The fourth probeset of four dinucleotides could comprise additional nucleotides,linkers, etc. however would lack a fluorescent moiety. The probes couldbe added to the sequencing by ligation reaction, ligated to the templateand a first image could be recorded to capture a first signal state. Acleavage reagent could be added to the reaction to cleave the secondcleavage site (e.g., SS linkage) thereby releasing the fluorescentmoiety, a hapten binding partner (for example streptavidin) conjugatedto a fluorescent moiety could be added and a second image could berecorded to capture a second signal state. A cleavage agent to the firstcleavage site (e.g., azide/alkoxy) could be added to the reaction torelease all the fluorescent moieties and the next round of sequencing byligation could be carried out. Signal states could be aligned andsequences determined.

Sequence by hybridization comprises the use of an array of shortsequences of nucleotide probes to which is added fragmented, labeledtarget DNA (Drmanac et al., 2002, Adv Biochem Eng Biotechnol 77:75-101;Lizardi et al., 2008, Nat Biotech 26:649-650; incorporated herein byreference in their entirety). The fragments hybridize to theircomplementary probe on the array and the hybridization is captured bythe attached label such as a fluorescent dye thereby determining thesequence of the target. Some applications of sequence by hybridizationutilize probes that comprise universal (e.g., nucleotide analogs) anddesignated nucleotides and are referred to as gapped probes, the use ofwhich is reported to increase the sensitivity of hybridization andthereby detection of the sequencing assay (U.S. Pat. No. 7,071,324,incorporated herein by reference in its entirety). Further improvementsto sequence by hybridization can be found at, for example, US patentapplication publications 2007/0178516, 2010/0063264 and 2006/0287833(incorporated herein by reference in their entireties). However,regardless of the method oftentimes complex optics systems are needed tocapture hybridization events.

The modified nucleotides disclosed herein could be utilized in sequenceby hybridization technologies. Nucleic acid probes from multipledifferent samples for sequence determination which are hybridized toarrayed probes could be modified to comprise attributes disclosed hereinfor use in minimal dye sequencing thereby allowing for less complexoptics with concurrent sequence determination of multiple different testsamples. For example, a test sample probe (e.g., fragmented test nucleicacids) could be modified to comprise a linker containing a cleavage site(for example an azide or alkoxy cleavage site) linking the probe with afluorescent moiety. A second probe set could be modified to comprise alinker containing two cleavage sites (the second cleavage site differentfrom the first, for example a SS linkage) linking the second probe witha fluorescent moiety. A third probe set could comprise a linkercontaining a cleavage site linking the nucleic acid probe with a haptenmoiety (for example biotin). The probes could be added to a sequence byhybridization type of array, hybridization reactions of the modifiedtest probes to the immobilized probes on the array carried out, and afirst image recorded to capture a first signal state. A cleavage reagentcould be added to the reaction to cleave the second cleavage site (e.g.,SS linkage) thereby releasing the fluorescent moiety, a hapten bindingpartner (for example streptavidin) conjugated to a fluorescent moietycould be added and a second image recorded to capture the second signalstate. Signal states could be determined, wherein the two image signalstate grid could be used to determine the location and thereby thesequence of the multiple different hybridized test probes.

Sequencing approaches which combine hybridization and ligationbiochemistries have been developed and commercialized, such as thegenomic sequencing technology practiced by Complete Genomics, MountainView, Calif.). For example, combinatorial probe-anchor ligation, orcPAL™ (Drmanac et al., 2010, Science 327(5961): 78-81) utilizes ligationbiochemistry while exploiting advantages of sequence by hybridization.Briefly, sequencing of the target DNA nanoballs comprises detectingligation products that are formed by an anchor oligonucleotide that ishybridized to an adaptor sequence which is subsequently ligated to afluorescently labeled degenerate sequencing probe comprising one of fourspecified nucleotides at the interrogation position. Ligation occurswhen the nucleotide at the interrogation position is complementary tothe nucleotide at the detection site within the target DNA nanoball. Theresulting stable probe/anchor ligation product is fluorescentlydetected. After the read, the entire anchor/probe complex is released,the next anchor is hybridized to the DNA target, and the process isrepeated. As with many sequencing reactions, four differently detectabledyes are utilized, one for each specified interrogation nucleotide A, C,G and T utilizing multiple detection optics.

The modified nucleotides disclosed herein could be utilized incombinatorial probe-anchor ligation sequencing technologies. Theincorporation of less than four dyes, would allow for fewer imagingevents. For example, a probe comprising a number or degeneratenucleotides could further comprise a linker containing a cleavage site(for example an azide or alkoxy cleavage site) linking the interrogationnucleotide with a fluorescent moiety. A probe comprising a second set ofdegenerate nucleotides could further comprise a linker containing twocleavage sites linking the interrogation nucleotide with a fluorescentmoiety. A probe set comprising a third set of degenerate nucleotidescould further comprise a linker containing a cleavage site linking theinterrogation nucleotide with a hapten moiety (for example biotin). Thefourth probe set of degenerate nucleotides could comprise additionalnucleotides, linkers, etc., however would lack a fluorescent moiety. Theprobes could be added to the cPAL™ reaction, ligated to theanchor/adaptor and a first image could be recorded to capture a firstsignal state. A cleavage reagent could be added to the reaction tocleave the second cleavage site (e.g., SS linkage) thereby releasing thefluorescent moiety, a hapten binding partner (for example streptavidin)conjugated to a fluorescent moiety could be added and a second imagecould be recorded to capture a second signal state. A cleavage agent tothe first cleavage site (e.g., azide/alkoxy) could be added to thereaction to release all the fluorescent moieties and the next round ofcPAL™ could be carried out. Signal states could be aligned and sequencesdetermined.

Nucleic acids or polynucleotides for sequencing include, but are notlimited to, nucleic acids such as DNA, RNA or PNA (peptide nucleicacid), variants or fragments thereof and/or concatamers thereof. Thepolynucleotides may be of known or unknown sequence, either naturallyoccurring or artificial in nature and can be of any source (e.g.,eukaryotic or prokaryotic). The polynucleotides may be naturallyderived, recombinantly produced or chemically synthesized.Concatamerized polynucleotides may contain subunits or analogs thereofthat may or may not occur in nature, or modified subunits. Methods asdescribed herein can be used to determine a sequence of apolynucleotide. The length of the target nucleic acid for sequencing mayvary. For example, the nucleic acid for sequencing may include at least10, at least 20, at least 30, at least 40, at least 50, at least 100, atleast 200, at least 500, at least 1,000, at least 10,000, at least100,000, at least 1,000,000, at least10,000,000 nucleotides. Thepolynucleotide for sequencing may be genomic in origin or fragments orvariants thereof. The nucleic acid strand for sequencing may be singlestranded and may or may not be derived from a double-stranded nucleicacid molecule. Single stranded molecules may also be produced by, forexample, chemical or in vitro synthesis methods and technologies.Embodiments as described herein are not limited by the nucleic acidpreparatory methods and any number methods may be practiced by a skilledartisan in order to provide a composition for use in disclosed methods.For example, in sequence by synthesis methodologies oftentimes a librarycomprising the target nucleic acids is generated, and a portion of theDNA library is then sequenced.

Isolated DNA from samples, for example genomic DNA containing samples,is typically modified prior to characterization, for example bysequencing utilizing methods as described herein. Genomic DNA librariesare created which can be sequenced by practicing the methods asdescribed herein. A library is produced, for example, by performing themethods as described in the Nextera™ DNA Sample Prep Kit (Epicentre®Biotechnologies, Madison Wis.), SOLiD™ Library Preparation Kits (AppliedBiosystems™ Life Technologies, Carlsbad Calif.), and the like. A DNAlibrary sample may be further amplified for sequencing by, for example,multiple stand displacement amplification (MDA) techniques.

For sequencing after MDA, an amplified sample library is, for example,prepared by creating a DNA library as described in Mate Pair LibraryPrep kit, Genomic DNA Sample Prep kits or TruSeq™ Sample Preparation andExome Enrichment kits (IIlumina®, Inc., San Diego Calif.).

DNA libraries can be immobilized on a flowcell and bridge amplificationperformed on the immobilized polynucleotides prior to sequencing, forexample sequence by synthesis methodologies. In bridge amplification, animmobilized polynucleotide (e.g., from a DNA library) is hybridized toan immobilized oligonucleotide primer. The 3′ end of the immobilizedpolynucleotide molecule provides the template for apolymerase-catalyzed, template-directed elongation reaction (e.g.,primer extension) extending from the immobilized oligonucleotide primer.The resulting double-stranded product “bridges” the two primers and bothstrands are covalently attached to the support. In the next cycle,following denaturation that yields a pair of single strands (theimmobilized template and the extended-primer product) immobilized to thesolid support, both immobilized strands can serve as templates for newprimer extension. Thus, the first and second portions can be amplifiedto produce a plurality of clusters. Clusters and colonies are usedinterchangeably and refer to a plurality of copies of a nucleic acidsequence and/or complements thereof attached to a surface. Typically,the cluster comprises a plurality of copies of a nucleic acid sequenceand/or complements thereof, attached via their 5′ termini to thesurface. Exemplary bridge amplification and clustering methodology aredescribed, for example, in PCT Patent Publ. Nos. WO00/18957 andWO98/44151, U.S. Pat. No. 5,641,658; U.S. Patent Publ. No. 2002/0055100;U.S. Pat. No. 7,115,400; U.S. Patent Publ. No. 2004/0096853; U.S. PatentPubl. No. 2005/0100900, U.S. Patent Publ. No. 2004/0002090; U.S. PatentPubl. No. 2007/0128624; and U.S. Patent Publ. No. 2008/0009420, each ofwhich is incorporated herein by reference in its entirety. Thecompositions and methods as described herein are particularly useful insequence by synthesis methodologies utilizing a flowcell comprisingclusters.

Emulsion PCR methods for amplifying nucleic acids prior to sequencingcan also be used in combination with methods and compositions asdescribed herein. Emulsion PCR comprises PCR amplification of an adaptorflanked shotgun DNA library in a water-in-oil emulsion. The PCR ismulti-template PCR; only a single primer pair is used. One of the PCRprimers is tethered to the surface (5′ attached) of microscale beads. Alow template concentration results in most bead-containing emulsionmicrovesicles having zero or one template molecule present. Inproductive emulsion microvesicles (an emulsion microvesicle where both abead and template molecule are present), PCR amplicons can be capturedto the surface of the bead. After breaking the emulsion, beads bearingamplification products can be selectively enriched. Each clonallyamplified bead will bear on its surface PCR products corresponding toamplification of a single molecule from the template library. Variousembodiments of emulsion PCR methods are set for in Dressman et al.,Proc. Natl. Acad. Sci. USA 100:8817-8822 (2003), PCT Patent Publ. No. WO05/010145, U.S. Patent Publ. Nos. 2005/0130173, 2005/0064460, andUS2005/0042648, each of which is incorporated herein by reference in itsentirety.

DNA nanoballs can also be used in combination with methods andcompositions as described herein. Methods for creating and utilizing DNAnanoballs for genomic sequencing can be found at, for example, USpatents and publications U.S. Pat. No. 7,910,354, 2009/0264299,2009/0011943, 2009/0005252, 2009/0155781, 2009/0118488 and as describedin Drmanac et al., 2010, Science 327(5961): 78-81; all of which areincorporated herein by reference in their entireties. Briefly, followinggenomic DNA fragmentation consecutive rounds of adaptor ligation,amplification and digestion results in head to tail concatamers ofmultiple copies of the circular genomic DNA template/adaptor sequenceswhich are circularized into single stranded DNA by ligation with acircle ligase and rolling circle amplified (as described in Lizardi etal., Nat. Genet. 19:225-232 (1998) and US 2007/0099208 A1, each of whichis incorporated herein by reference in its entirety). The adaptorstructure of the concatamers promotes coiling of the single stranded DNAthereby creating compact DNA nanoballs. The DNA nanoballs can becaptured on substrates, preferably to create an ordered or patternedarray such that distance between each nanoball is maintained therebyallowing sequencing of the separate DNA nanoballs.

A skilled artisan will recognize additional methods and technologies foramplifying nucleic acids which could also be used in combination withthe methods and compositions described herein. Embodiments describedherein are not limited to any DNA amplification method.

Methods as described herein are not limited by any particular sequencingsample preparation method and alternatives will be readily apparent to askilled artisan and are considered within the scope of the presentdisclosure. However, particular utility is found when applying themethods herein to sequencing devices such as flow cells or arrays forpracticing sequence by synthesis methodologies or other relatedsequencing technologies such as those practiced by one or more of polonysequencing technology (Dover Systems), sequencing by hybridizationfluorescent platforms (Complete Genomics), sTOP technology (IndustrialTechnology Research Institute) and sequencing by synthesis (Illumina,Life Technologies).

In some embodiments, the methods set forth herein can be used in amodified version of manufacturer's protocols on a system such as thoseprovided by Illumina®, Inc. (HiSeq 1000, HiSeq 2000, Genome Analyzers,MiSeq, HiScan, iScan, BeadExpress systems), Applied Biosystems™ LifeTechnologies (ABI PRISM® Sequence detection systems, SOLiD™ System), orother fluorescence based sequencing instrument, further as thosedescribed in, for example, United States patents and patent applicationsU.S. Pat. Nos. 5,888,737, 6,175,002, 5,695,934, 6,140,489, 5,863,722,2007/007991, 2009/0247414, 2010/0111768 and PCT applicationWO2007/123744, and U.S. patent application Ser. Nos. 61/431,425,61/431,440, 61/431,439, 61/431,429, 61/438,486 each of which isincorporated herein by reference in its entirety. Modifications to thecommercial methods can include, but are not limited to, alteration ofthe labels used and addition of steps to change label states as setforth herein.

Output from a sequencing instrument can be of any sort. For example,current technology typically utilizes a light generating readableoutput, such as fluorescence or luminescence, however the presentmethods are not limited to the type of readable output as long asdifferences in output signal for a particular sequence of interest ispotentially determinable. Examples of analysis software that may be usedto characterize output derived from practicing methods as describedherein include, but are not limited to, Pipeline, CASAVA andGenomeStudio data analysis software (IIlumina®, Inc.), SOLiD™, DNASTAR®SeqMan® NGen® and Partek® Genomics Suite™ data analysis software (LifeTechnologies), Feature Extraction and Agilent Genomics Workbench dataanalysis software (Agilent Technologies), Genotyping Console™,Chromosome Analysis Suite data analysis software (Affymetrix®).

A skilled artisan will know of additional numerous commercially andacademically available software alternatives for data analysis forsequencing generated output. Embodiments described herein are notlimited to any data analysis method.

EXAMPLES

The following examples are provided in order to demonstrate and furtherillustrate certain embodiments and aspects of the present disclosure andare not to be construed as limiting the scope thereof.

Example 1 Synthesis of rbATP-LN3-DEG527-PEG4-Biotin

A branched biotinylated and fluorescently labeled, reversibly blockedadenine construct for use in SBS was synthesized as follows:

Lys-DEG527

To a solution of DEG527 (11 mg, 14.6 μmol) in dry DMA (2 ml) was addedTSTU (5.3 mg, 17.5 μmol) and diisopropylethylamine (6.3 μl, 36.5 μmol).The mixture was stirred for 30 minutes at room temperature to fullactivation of the acid. A solution of Boc-lysine (18 mg, 73 μmol) inTEAB 0.1 M (0.2 ml) was added to the reaction mixture. The mixture wasstirred for 3 hours until TCL showed complete consumption of activatedester. The volatiles were evaporated under reduced pressure and theresidue was dissolved in trifluoroacetic acid (0.1 ml), DCM (0.9 ml) andMeOH (0.1 ml). The solution was stirred at room temperature for 1 houruntil TLC showed full consumption of the starting material. The solutionwas concentrated down to dryness, re-dissolved in TEAB 0.1 M (5 ml) andpurified by RP-HPLC.

Lys-DEG527-PEG4-Biotin

To a solution of Lys-DEG527 (14 μmol) and diisopropylethylamine (15 μl,84 μmol) in dry DMA (5 ml), was added PEG4-biotin-NHS (41 mg, 70 μmol).The mixture was sonicated for several minutes and then continuouslystirred for several hours. TCL showed complete consumption oflys-DEG527. The volatiles were evaporated under reduced pressure. Theresidue was re-dissolved in TEAB 0.1 M (5 ml) and purified by RP-HPLC.

rbATP-LN3-DEG527-PEG4-Biotin

To a solution of Lys-DEG527-PEG4-biotin (9 μmol) in dry DMA (2 ml), wasadded TSTU (3.3 mg, 10.8 μmol) and diisopropylethylamine (4 μl, 22.5μmol). The mixture was stirred for 30 minutes at room temperature tofull activation of the acid. A solution of LN3-pppA (14 μmol) in TEAB0.1 M (0.2 ml) was added to the reaction mixture. The mixture wasstirred for 5 hours until TCL showed complete consumption of activatedester. The reaction was quenched with TEAB buffer (0.1M, 10 ml) andloaded on a DEAE Sephadex column (2×5 cm). The column was eluted with agradient of 0.1M to 1M TEAB buffer in 30 min at 25 ml/min. The fractionscontaining the product were combined, evaporated and purified by HPLC.

Example 2 Synthesis of rbCTP-LN3-PEG4-Biotin

A biotinylated, reversibly blocked cytosine construct for use in SBS wassynthesized as follows:

rbCTP-LN3-PEG4-Biotin

To a solution of PEG4-biotin-NHS (17.7 mg, 30 μmol) anddiisopropylethylamine (8.7 μl, 50 μmol) in dry DMA (3 ml), was added asolution of LN3-pppC (10 μmol) in TEAB 0.1M (0.3 ml). The mixture wasstirred at room temperature for 5 hours. The reaction progress wasmonitored by RP-HPLC until complete consumption of LN3-pppC. Thereaction was quenched with TEAB buffer (0.1M, 10 ml) and loaded on aDEAE Sephadex column (2×5cm). The column was eluted with a gradient of0.1M to 1M TEAB buffer in 30 min at 25 ml/min. The fractions containingthe product were combined, evaporated and purified by HPLC.

Example 3 Synthesis of rbATP-LN3-SS-DEG527

A fluorescently labeled, fully functional adenine construct comprising acleavable linker for use in SBS was synthesized as follows:

DEG527-SS-linker

To a solution of DEG527 (12.5 mg, 14 μmol) in dry DMA (2 ml), was addedTSTU (6 mg, 20 μmol) and diisopropylethylamine (7 μl, 40 μmol). Themixture was stirred for 30 minutes room temperature to full activationof the acid. A solution of SS-linker (9 mg, 50 μmol) in TEAB 0.1M (0.2ml) was added to the reaction mixture. The mixture was stirred for 3hours until TCL showed complete consumption of activated ester. Thevolatiles were evaporated under reduced pressure and the residue wasdissolved in TEAB 0.1M (5 ml) and purified by RP-HPLC.

rbATP-LN3-SS-DEG527

To a solution of DEG527-SS-linker (5.9 μmol) in dry DMA (2 ml), wasadded TSTU (2.1 mg, 7.1 μmol) and diisopropylethylamine (2.6 μl, 14.8μmol). The mixture was stirred for 30 minutes at room temperature tofull activation of the acid. A solution of LN3-pppA (17.7 μmol) in TEAB0.1M (0.2 ml) was added to the reaction mixture. The mixture was stirredfor 5 hours until TCL showed complete consumption of activated ester.The reaction was quenched with TEAB buffer (0.1M, 10 ml) and loaded on aDEAE Sephadex column (2×5cm). The column was eluted with a gradient of0.1M to 1M TEAB buffer in 30 min at 25ml/min. The fractions containingthe product were combined, evaporated and purified by HPLC.

Example 4 Detection of Nucleotide Incorporation Using Biotin ConjugatedNucleotide Construct

Experiments were performed to demonstrate the use of a biotin conjugatednucleotide in sequencing reactions. The time space signature of theexperiments followed the time space imaging pattern

Image 1 Image 2 A 1 0 C 0 1 G 0 0 T 1 1

Experiments were performed on a Genome Analyzer IIx configured insingle-lane mode. A standard sequence by synthesis enzymologyincorporation program was followed using the reversibly blockednucleotide mix including an unlabelled rbGTP, fluorescently labeledrbTTP-LN3-NR550, biotinylated rbCTP-LN3-PEG4-biotin and rbATP with acleavable disulfide (SS) linker rbATP-LN3-SS-DEG527. Data acquisitionand analysis differed from the standard 4-dye SBS chemistry. Briefly,after a nucleotide incorporation step, the clusters were laser excitedand a fluorescent image was acquired. Additional reaction componentswere added to the reaction to selectively cleave the SS bond ofrbATP-LN3-SS-DEG527 and SA-NR555 was added to selectively labelrbCTP-LN3-biotin to create rbCTP-LN3-biotin-SA-NR555. The clusters werelaser excited a second time a second fluorescent image was recorded. So,incorporation of each of the four bases is by changes, or lack thereof,of fluorescent intensity states using dyes that excite and emit in thesame wavelength.

A genomic DNA library was created for use in single read sequencing on aGenome Analyzer IIx (Illumina, Inc.). Following library preparation, asequencing flowcell with target sequencing clusters was creating usingthe TruSeq SR Cluster Kit v2 on the Illumina® cBot followingmanufacturer's protocol for single read sequencing. Following clustergeneration, the flowcell was placed in a Genome Analyzer IIx and thesample was sequenced using reagents from TruSeq SBS Reagent Kit v5(Illumina®, Inc.).

Stock solutions of the reversibly blocked nucleotides for use in thesequencing reaction were prepared; 100 μM stock solutions of dark orunlabelled rbGTP, rbATP-LN3-SS-DEG527, rbCTP-PEG4-biotin andrbTTP-LN3-NR550. A stock solution of streptavidin-NR555 (SA-NR555 at 1mg/ml) was prepared in a Binding and Wash buffer (5 mM Tris pH 7.5, 0.5mM EDTA, 1M NaCl).

For the Genome Analyzer IIx, the instrument reagent positions werere-configured for single dye sequence by synthesis. One lane wasselected for sequencing and the other lanes were disconnected therebyensuring that reagents were drawn through one sequencing lane and thatno cross-over of any liquid from another lane could occur. Reagents wereplaced on the Genome Analyzer IIx (GAIIx) as follows:

Position Reagent 1 Incorporation Mix (IMX) 2 Blank 3 Scan Mix (SMX) 4Blank 5 Incorporation Buffer (PR2) 6 Cleavage Mix (CLM) 7 Blank 8SA-NR555

Reagents were prepared for a 150 cycle sequencing assay. From the TruSeqSBS Reagent Kit v5, reagents CLM, SMX and PR2 were utilized asinstructed. For the IMX reagent containing the reversibly blockednucleotides, to 20.1 ml of IMX buffer was added 1 ml of rbATP-SS-DEG527(final concentration 4 μM), 0.5 ml rbGTP (final concentration 2 μM), 2.5ml rbCTP-PEG4-biotin (final concentration 10 μM) and 0.25 mlrbTTP-LN3-NR550 (final concentration 1 μM). The rbNTP solution wasfiltered and 0.6 ml of High Density polymerase (HDP, final concentration15 μg/ml) was added. A 1:200 dilution of SA-NR555 was made in Bindingand Wash buffer.

Reagents were loaded on the Genome Analyzer IIx and sequencing protocolwas run. Briefly, a standard incorporation step (i.e., FirstBase) wasfollowed by imaging as described in the manufacturer's protocol. Theimaging was immediately followed by disulphide cleavage (addition ofCLM) and SA-NR555 (addition of 1:200 dilution SA-NR555) binding and asubsequent second imaging followed by a standard de-block andincorporation step (i.e., CompleteCycle). Cleavage of the disulphidebonds resulting in a change in intensity state for rbATP from 1 to 0 wasselective and proceeded at a rapid rate of <5 seconds at roomtemperature. Biotin/streptavidin binding also occurring rapidly at arate of <25 seconds at room temperature resulting in a change inintensity state for rbCTP from 0 to 1.

Total cycle time excluding imaging was around 9.3 minutes. Cycling wasrepeated for the remaining cycles. The general flow is illustrated inFIG. 11.

Exemplary results can be found in FIGS. 1 and 2 and Table 1. FIG. 1exemplifies a cloud style heat map recorded at different cyclesthroughout the sequencing run. The cloud maps demonstrate thatdifferentiation of the four nucleotides was successful (the bottomisolated and nucleotide labeled cloud map orients the positions of thefour nucleotides within the cloud map). FIG. 2 reports an exemplarytracking of error rate percentages of nucleotide incorporation over a100 cycle sequencing run for the selected lane 4, tile 4. An error rateof 0.4% over 100 cycles for lane 4, tile 4 on a flowcell was recorded,whereas FIG. 2 demonstrates that there were no blank base callsthroughout the 100 cycle run for that lane and tile. Phasing wasreported at 0.27% and prephasing at 0.43%. Table 1 shows results fromlane 4, tiles 1-6.

TABLE 1 % Av % Error Clusters % PF Align Alignment Rate Lane Tile (raw)Clusters (PF) Score (PF) (PF) 4 1 288360 77.64 96.08 121.87 0.51 4 2285563 78.67 96.04 121.39 0.7 4 3 282653 79.5 96.12 121.97 0.48 4 4280818 79.07 95.92 121.87 0.4 4 5 283422 78.36 96.05 121.97 0.43 4 6282958 61.68 60.7 74.58 2.22

Example 5 Detection of Nucleotide Incorporation Using One Dye

Experiments were performed to demonstrate that one dye can be used todetermine the sequence of a nucleic acid.

The nucleotides utilized in this experiment included:

rbATP-LN3-SS-NR550C4

rbTTP-LN3-NR550C4

rbCTP-(LN3)²-Biotin

rbGTP-no label

All nucleotide stock concentrations were stored at 100 μM in 10 mM TrisBuffer (pH 8.0).

The fluorescent moiety used to label the nucleotides was NR550C4. Tworepresentative emission spectra for the dye on rbATP and rbTTP are shownin FIG. 5B. The rbGTP was not labeled and therefore was considered the“dark” nucleotide. For determining the incorporation of cytosines into agrowing nucleic acid strand, a master mix which included a conjugate ofstreptavidin-NR550C4 was added to the reaction as detailed below.

Synthesis of the NR550C4-SS-linker composition was performed aspreviously described for DEG527-SS-linker composition, except theNR550C4 fluorescent moiety was used in lieu of the DEG527 fluorophore.Synthesis of the rbATP-LN3-SS-NR550C4 composition was performed aspreviously described for rbATP-LN3-SS-DEG527, however theNR550C4-SS-linker composition was used in lieu of the DEG527-SS-linkercomposition. Synthesis of the rbTTP-LN3-NR550C4 composition wasperformed as described for rbATP-LN3-SS-550C4, however rbTTP-LN3 wasused in lieu of rbATP-LN3 and NR550C4 was used in lieu ofNR550C4-SS-linker. Synthesis of the rbCTP-(LN3)²-Biotin was performed aspreviously described for rbCTP-LN3-PEG4-Biotin, except that LN3-Biotinwas used instead of biotin during the amide coupling reaction.

Streptavidin was conjugated to NR550C4 by methods known in the art, anda stock solution of Strep-NR550C4 (SA-NR550C4) at 1 mg/ml was preparedin a buffer of 5 mM Tris pH 7.5, 0.5 mM EDTA and 1M NaCl.

To the IMX reagent, stock solutions of the nucleotide compositions wereadded to yield the final concentrations of 2 μM rbATP-LN3-SS-NR550C4, 10μM rbCTP-(LN3)²-Biotin, 1 μM rbTTP-LN3-NR550C4 and 2 μM rbGTP-dark.Additionally, 15 μg/ml of a High Density polymerase was added to theIMX/nucleotide reagent. CLM, SMX and PR2 reagents were as previouslydescribed. A master mix, SA-NR550C4-Cleavage Mix, was prepared bydiluting SA-NR550C4 to a final concentration of 5 μg/ml in 2 mM THP, 5mM Tris pH 7.4, 1M NaCl, 0.5 mM EDTA and 0.005% Tween.

The one dye sequencing experiments were run on a MiSeg™ sequencinginstrument (I lumina, Inc.). The position of the reagents on theinstrument was:

1-IMX

2-SRE (Scan Mix)

3-PR2

4-CLM

18-SA-NR550C4-Cleavage Mix

The instrument was set at 60° C. at the beginning of the sequencingexperiments and all of the sequencing steps including imaging steps werecarried out at this temperature for isothermal sequencing. Theisothermal sequencing performed comparably to sequencing performed onthe GAIIx as previously described, where imaging took place at 22° C.

For MiSeg™ sequencing, total SBS chemistry cycle time for oneincorporation cycle (excluding imaging cycles) was 3.37 minutes (ldyeSBS was 2.70 minutes and SA labelling and cleavage was 0.67 seconds).The sequencing cycles were repeated basically as described in FIG. 12.

Results from the one dye sequencing experiment can be found in FIGS.5A&D and Table 2. Phasing was reported at 0.17% and prephasing at 0.36%.Table 2 shows results from lane 1, tiles 1-4.

TABLE 2 % Av % Error Clusters % PF Align Alignment Rate Lane Tile (raw)Clusters (PF) Score (PF) (PF) 1 1 331576 71.85 90.85 673.37 2.13 1 2331383 71.51 91.11 677.41 2.09 1 3 334956 72.19 90.87 676.4 2.07 1 4333278 72.74 90.97 671.76 2.18

FIG. 5A shows an example of tracking of error rate percentages ofbasecalls over a 150 cycle sequencing run for a tile. An error rate ofapproximately 2.12% over 150 cycles was seen. Based on the experimentaldesign, FIGS. 5B and C show exemplary imaging events of detectionpatterns that should result for the different modified nucleotides foreach of the imaging events. For example, FIG. 5B Image 1 shows that thefirst image event should capture no, or minimal, fluorescence for rbGTPor rbCTP-(LN3)²-Biotin as they are not associated with any fluorescentmoiety prior to the first imaging event and fluorescence for the rbATPand rbTTP labeled nucleotides as they are associated with a fluorescentmoiety prior to the first imaging event. FIG. 6C Image 2 shows thatfollowing the addition of the SA-NR550C4-Cleavage Mix there should beno, or minimal, fluorescence from the rbATP modified nucleotide as thedisulfide in the rbATP-LN3-SS-NR550C4 composition should be cleavedthereby releasing the attached fluorophore and the incorporation of therbCTP into the growing nucleic acid strand would be detectable due tothe binding of the SA-NR550C4 composition to the biotin on therbCTP-(LN3)²-Biotin conjugate. The rbGTP and rbTTP-LN3-NR550C4fluorescent patterns should remain the same from Image 1 to Image2 whenfollowing the experimental design described in this Example.

FIG. 5D shows a cloud plot demonstrating that, surprisingly, thefluorescence detection pattern did follow the proposed image pattern andthat each of the nucleotides could be differentiated one from the otherwhen incorporated into a growing nucleotide strand using only one dyeand two imaging events in a sequencing experiment.

These results reported in this disclosure demonstrate that sequencing ofa nucleic acid can be accomplished by using as few as one fluorescentdye and less than four imaging events to differentiate the incorporationof all four different nucleic acids in a sequencing cycle.

All publications and patents mentioned in the present application areherein incorporated by reference. Various modifications and variationsof the described methods and compositions will be apparent to thoseskilled in the art without departing from the scope and spirit of thedisclosure. Although the invention has been described in connection withspecific preferred embodiments, it should be understood that theinvention as claimed should not be unduly limited to such specificembodiments. Indeed, various modifications of the described embodimentsthat are obvious to those skilled in the relevant fields are intended tobe within the scope of the following claims.

1. A method for determining the sequence of a polynucleotide comprisingdetecting in a sequencing reaction the incorporation of three differenttypes of detectable nucleotide conjugates into a polynucleotide anddetermining the incorporation of a fourth type of nucleotide based onthe detection pattern of the three different types of detectablenucleotides into the polynucleotide thereby determining the sequence ofa polynucleotide, wherein the incorporation of three different types ofdetectable nucleotide conjugates is detected from a signal state andwherein the incorporation of the fourth type of nucleotide is determinedfrom a dark state.
 2. The method of claim 1, wherein the nucleotideconjugate comprises nucleotide types selected from the group consistingof dATP, dTTP, dUTP, dCTP, dGTP or non-natural nucleotide analogsthereof.
 3. The method of claim 2, where the non-natural nucleotideanalog comprises a reversible terminator moiety and is selected from thegroup consisting of rbATP, rbTTP, rbUTP, rbCTP and rbGTP.
 4. The methodof claim 1, wherein the three nucleotide conjugates are detected bydetecting a fluorescent moiety.
 5. The method of claim 4, wherein thefluorescent moiety is the same for the three nucleotide conjugates orwherein the fluorescent moiety is one or more different fluorescentmoieties.
 6. The method of claim 5, wherein the one or more differentfluorescent moieties are detected by one or more emission filters. 7.The method of claim 5, wherein the incorporation of the fourthnucleotide is determined by the fluorescent detection pattern of thefluorescent moiety.
 8. The method of claim 7, wherein the fluorescencedetection pattern is determined by a first and a second imaging event.9. The method of claim 8, wherein the first imaging event detects apattern of fluorescence that is different from the pattern offluorescence detected by the second imaging event.
 10. The method ofclaim 9, wherein the incorporation of one or more nucleotides isdetermined by the difference in the pattern of fluorescence between thefirst and second imaging events.
 11. The method of claim 1, wherein theone or more nucleotide type conjugates further comprise one or morelinker sequences.
 12. The method of claim 11, wherein the one or morelinker sequences comprises one or more of a cleavable linker and aspacer linker wherein the cleavable linker comprises one or morecleavable linkage groups selected from the group consisting of adisulfide, a diol, a diazo, an ester, a sulfone, an azide, an alyl and asilyl ether.
 13. The method of claim 12, wherein the spacer linker isone or more of polyethylene glycol or concatamers thereof and2-{2-[3-(2-amino-ethylcarbomyl)-phenoxyl-1-azido-ethoxy}-ethoxy-aceticacid.
 14. The method of claim 12, wherein the one or more spacer linkersfurther comprise one or more cleavable linkage groups wherein thecleavable linkage group is selected from the group consisting of adisulfide, a diol, a diazo, an ester, a sulfone, an azide, an alyl and asilyl ether.
 15. The method of claim 13, wherein the one or morenucleotide conjugates comprise a polyethylene glycol linker and a2-{2-[3-(2-amino-ethylcarbomyl)-phenoxyl-1-azido-ethoxy}-ethoxy-aceticacid linker.
 16. The method of claim 15, wherein the nucleotideconjugate comprising a polyethylene glycol linker and a2-{2-[3-(2-amino-ethylcarbomyl)-phenoxyl-1-azido-ethoxy}-ethoxy-aceticacid linker further comprises a hapten and a fluorescent moiety.
 17. Themethod of claim 16, wherein the hapten is selected from the groupconsisting of biotin, digoxigenin and dinitrophenol.
 18. The method ofclaim 17, wherein the one or more nucleotide conjugates comprises astreptavidin-fluorescent moiety conjugate.
 19. A method for determiningthe sequence of a polynucleotide comprising: a) applying to apolynucleotide sample for sequencing a solution comprising four modifiednucleotide types wherein three modified nucleotide types are conjugatedto one or more detection moieties and one or more linkers positionedbetween the nucleotide and the one or more detection moieties, andwherein a fourth nucleotide type lacks a detection moiety, b) detectinga pattern of incorporation of said modified nucleotides in a sequencingreaction thereby capturing a first detectable pattern, c) applying oneor more compositions to the sequencing reaction thereby changing thefirst detectable pattern, d) detecting a second detectable pattern, ande) determining the sequence of the polynucleotide sample based on thedetectable patterns.
 20. The method of claim 19, wherein the modifiednucleotide types are selected from the list comprising rbATP, rbTTP,rbUTP, rbCTP and rbGTP.
 21. The method of claim 19, wherein the one ormore detection moieties is a fluorescent moiety.
 22. The method of claim21, wherein the fluorescent moiety is the same or the fluorescent moietyis one or more different fluorescent moieties.
 23. The method of claim22, wherein the one or more different fluorescent moieties are detectedby one or more emission filters.
 24. The method of claim 19, whereinsaid detecting is an imaging event and wherein the detectable patternsare fluorescent patterns.
 25. The method of claim 24, whereinincorporation of the fourth nucleotide type is determined by thefluorescence detection patterns of the other three nucleotide types inboth the first and second detectable patterns.
 26. The method of claim19, wherein the one or more nucleotide type conjugates further compriseone or more linker sequences.
 27. The method of claim 26, wherein theone or more linkers comprise one or more of a cleavable linker and aspacer linker.
 28. The method of claim 27, wherein the cleavable linkercomprises one or more cleavable linkage groups from the group consistingof a disulfide, a diol, a diazo, an ester, a sulfone, an azide, an alyland a silyl ether.
 29. The method of claim 27, wherein the spacer linkeris one or more of polyethylene glycol or concatamers thereof and2-{2-[3-(2-amino-ethylcarbomyl)-phenoxyl-1-azido-ethoxy}-ethoxy-aceticacid.
 30. The method of claim 29, wherein the one or more spacer linkersfurther comprise one or more cleavable linkage groups.
 31. The method ofclaim 30, wherein the cleavable linkage group is selected from the groupconsisting of a disulfide, a diol, a diazo, an ester, a sulfone, anazide, an alyl and a silyl ether.
 32. The method of claim 29, whereinthe one or more nucleotide type conjugates comprise a polyethyleneglycol linker and a2-{2-[3-(2-amino-ethylcarbomyl)-phenoxyl-1-azido-ethoxy}-ethoxy-aceticacid linker.
 33. The method of claim 32, wherein the nucleotide typeconjugate comprising a polyethylene glycol linker and a2-{2-[3-(2-amino-ethylcarbomyl)-phenoxyl-1-azido-ethoxy}-ethoxy-aceticacid linker further comprises a hapten and a fluorescent moiety.
 34. Themethod of claim 33, wherein the hapten is selected from the groupconsisting of biotin, digoxigenin and dinitrophenol.
 35. The method ofclaim 34, wherein said detecting further comprises a streptavidin-fluorescent moiety conjugate.
 36. The method of claim 19, wherein theone or more compositions added to a sequencing reaction thereby changingthe first detectable pattern comprises adding one or more of a cleavagecompound and a binding partner-detection moiety conjugate.
 37. Themethod of claim 36, wherein the cleavage compound is a reducing agentcomprising one or more compositions selected from the group consistingof dithioerythritol, dithiothreitol, 2-mercaptoethanol, glutathione,thioglycolic acid, 2,3-dimercaptopropanol and tris(2-carboxyethyl)phosphine.
 38. The method of claim 36, wherein thebinding partner-detection moiety conjugate is selected from the groupconsisting of a streptavidin-fluorescent moiety conjugate, ananti-digoxigenin-fluorescent moiety conjugate and ananti-dinitrophenol-fluorescent moiety conjugate.
 39. A composition forsequencing a nucleic acid comprising three different modified nucleotidetype conjugates comprising a fluorescent moiety and a fourth differentmodified nucleotide type, wherein said fourth different modifiednucleotide type lacks a fluorescent moiety, and wherein theincorporation of the four modified nucleotide types in the compositioninto a sequencing reaction is determined by the fluorescent detection ofthe three different modified nucleotide type conjugates comprising afluorescent moiety in the composition.
 40. The composition of claim 39,wherein the fluorescent moiety is the same for the three modifiednucleotides or the fluorescent moiety is one or more differentfluorescent moieties.
 41. A method for determining the sequence of apolynucleotide comprising the composition of claim 39, comprising: a)detecting by one or more imaging events the incorporation of the threedifferent types of detectable nucleotide type conjugates into apolynucleotide and b) determining the incorporation of the fourth typeof nucleotide based on the detection pattern of the three differenttypes of detectable nucleotide type conjugates into a polynucleotide,wherein detecting comprises fewer imaging events than different types ofnucleotides.
 42. The method of claim 41, wherein the fluorescent moietyis the same for the three nucleotide conjugates or the fluorescentmoiety is one or more different fluorescent moieties.
 43. The method ofclaim 42, wherein the incorporation of the fourth nucleotide isdetermined by lack of detection.
 44. The method of claim 41, whereinsaid imaging events comprise a first and a second imaging event.
 45. Themethod of claim 44, wherein the first imaging event detects a pattern offluorescence that is different from the pattern of fluorescence detectedby the second imaging event.
 46. The method of claim 45, wherein theincorporation of one or more nucleotides is determined by the differencein the pattern of fluorescence between the first and second imagingevents.